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Organophosphates (OPs) are a class of compounds that have been predominantly 
used as insecticides but also as chemical warfare agents. They covalently inhibit the 
enzyme acetylcholinesterase (AChE) which plays a key role in terminating muscle 
contractions. Due to the toxic nature of these compounds, methods are needed that 
can assess the threat posed by new OPs and inform on the effectiveness of medical 
countermeasures.  
In this project the recombinant expression and purification of a mutated isoform of 
AChE (AChE-d) was optimised to allow in vitro kinetic assays to be carried out on OP 
inhibition of AChE-d and the reactivation of the OP-AChE-d conjugates by oximes. 
The isotopic labelling of AChE-d was optimised resulting in 15N uniformly labelled 
AChE-d being produced. Heteronuclear 2D NMR spectra were collected of labelled 
AChE-d inhibited by OPs. This data was analysed along with the reactivation data to 
determin if OPs with similar reactivation rates caused similar peaks to shift. 
Saturation transfer difference (STD) NMR spectra were collected on an AChE-d 
mutant that could not be phosphorylated by OPs. 
The inhibition rates of OPs did not correlate with their toxicity. The reactivation data 
for AChE-d differed from data collected using human AChE. The NMR spectra of OP 
inhibited AChE-d indicated that reactivation resistant OPs did cause similar peak 
shifts but further investigation is needed to confirm this due to the low 
resolution/signal of the NMR spectra. STD data indicated that phosphorylation was 




1. Chapter 1 Introduction 
1.1 Acetylcholinesterase (AChE) variants, 
mechanism of action and importance in disease. 
1.1.1 Isoforms of AChE. 
In mammals there are three isoforms of AChE. AChE-S (for synaptic) is found at the 
neuromuscular junction and cholinergic synapses in the brain, it contains a cysteine 
at the C-terminus that forms a covalent dimer with another AChE, this dimer can 
then non-covalently bind to another covalent dimer of AChEs to form a tetramer (1). 
A proline rich collagen-like domain binds exon 6 (Figure 1) of the AChEs in the 
tetramer and anchors it to the post synaptic membrane (2). This isoform is 
particularly prevalent in the neuromuscular junction where it hydrolyses the 
neurotransmitter acetylcholine (ACh) (Figure 2), this terminates muscle contractions 
(3).  
AChE is also found bound to the outer membrane of erythrocytes by a 
Glycosylphosphatidylinositol (GPI) anchor (4), this isoform is referred to as AChE-E 
(for erythrocyte). The physiological role of AChE-E isn’t definitively known, but the 
presence of ACh in plasma has been shown to increase NO efflux from erythrocyte 
and, the NO efflux has been shown to stop when AChE inhibitors were added to the 
assay, indicating that the breakdown of ACh by AChE-E stimulates the signal cascade 
that results in NO efflux from erythrocytes (5). NO stimulates vasodilation (6) which 
could indicate that AChE-E has a role in increasing blood flow to tissues exposed to 
high concentrations of ACh, for example contracting muscles.  
A soluble monomer of AChE also exists, called AChE-R (for read-through). This 
isoform is the result of an intron 4 (Figure 1) being incorporated into the enzyme. 
Like AChE-E the exact function of this isoform isn’t known but it has been shown to 
be overexpressed in mice after psychological and chemical stress (7) and certain 




isoform (8). This indicates that AChE-R is expressed in response to certain stress but 
doesn’t explain its function.  
 
Figure 1. A schematic diagram showing the AChE gene and the three different mRNAs that arise 
from its alternative splicing. I stands for intron and E stands for exon. This Figure is an altered 
version of one found in reference (9). 
This nomenclature based on physiological role and localisation is useful when 
comparing AChE isoforms within mammals but problems are encountered when 
comparing the AChE isoforms of distant species. For example Drosophila has a single 
AChE isoform which is only found in the synaptic cleft of cholinergic neurons  
meaning functionally it would be classed as AChE-S, but structurally it shows more 
similarity to the AChE-E isoform in mammals (10). A second nomenclature exists 
based on the structure of the isoform and its mode of anchoring to membranes, an 
overview of this is shown in Figure 3. In this nomenclature AChE-H (for hydrophobic) 
is used to describe AChE isoforms that have a hydrophobic C-terminus containing a 
Cys that allows the formation of a covalent dimer and a GPI anchor which fixes the 
isoform to the membrane (11). Mammalian AChE-E and Drosophila AChE are 
examples of AChE-H. 
The C-terminus of AChE-T (for tailed) contains a Cys residues which allows the 
formation of a dimer which can then form a tetramer with another AChE-T dimer. 
The C-terminus also contains the residues necessary for association with collagen 
and other similar proteins which can anchor the tetramer to the membrane or form 
larger bundles of tetramers (Figure 3 AChE-T 5) (12)(2). AChE-T 1,2 and 4 in Figure 3 




expressed in the absence of a collagen-like binding partner (2). Mammalian AChE-S 
is included in this category.  
Confusingly AChE-S (for snake or soluble) is also used in this nomenclature. It’s a 
monomeric form of AChE possessing a highly charged C-terminus that’s missing the 
usual Cys residue. AChE-S is only found in Elapid snake venom where its purpose is a 
mystery since it doesn’t add any toxicity to the venom (13). All future uses of AChE-
S will be referring to the synaptic isoform of AChE.  
Vertebrates also contain a second type of cholinesterase called 
butyrylcholinesterase (BChE), this enzyme is predominantly found in plasma but also 
exists in the brain (14). Unlike AChE-S, the activity of BChE doesn’t appear to be vital 
for the survival as around 4% of the human population have a genotype that reduces 
BChE activity by a factor of 10, and the only negative phenotype associated with this 
genotype is an increased sensitivity to the muscle relaxant succinylcholine which is 
commonly administered along with an anaesthetic to patients undergoing surgery 
(15). 
The three different mammalian isoforms of AChE (S, E and R) have very similar kinetic 
properties (16) for inhibition with Diisopropyl fluorophosphate (DFP). This is 
unsurprising since only the C-terminus of these isoforms (exons 5 and 6,    Figure 1) 
are altered, these exons encode residues responsible for dimerization and method 
of attachment to membranes (9). The AChE from different species shows a larger 
variation in kinetic parameters. The sarin inhibition rate for rhesus monkeys AChE-S 
was shown to be  3 times higher than guinea pig and 2 times higher than pig AChE-S 
(17). This shows that AChE from a single species needs to be used in a set of 
experiments and care needs to be taken when extrapolating AChE kinetic data from 
one species to another.  
 





Figure 3. A cartoon representation of the different quaternary structures of AChE isoforms and their 
varying methods of associating with membranes. AChE-H (for hydrophobic) has a hydrophobic C-
terminus that contains a post translational modification site for GPI that anchors it to the 
membrane, AChE-T (for tailed) contains a C-terminal peptide that allows association with a college 
like protein meaning higher order oligomeric structures can be formed and AChE-S (for soluble or 
snake) contains a highly charged C-terminus that lacks a Cys residue so can’t form dimers. This figure 
is an altered version of one found in reference (2). 
1.1.2 AChE structure and activity 
The rate that AChE breaks down ACh is remarkably fast. The catalytic rate (kcat/Km) 
of AChE for ACh is around 1 X 108 M/s (18) this is higher than the average catalytic 
rate of 1 X 105 M/s (19), and is close to the diffusion limited rate of 1.5 X 1010 M/s 
(20). The high catalytic rate of AChE is particularly surprising as its active site is 
located at the bottom of a deep gorge shown in Figure 4 A.  
Some studies have suggested mechanisms to explain how the presence of the active 
site gorge could increase the catalytic rate. First of all, the presence of a relatively 
weak binding site for ACh was discovered at the top of the gorge (Figure 4 B and 
Figure 5), it’s been suggested that ACh first interacts with this before being passed 
down the gorge (21). The gorge itself contains several highly conserved acidic 
residues that are positioned to create a charge gradient with the strongest negative 
charge being at the base of the gorge (Figure 5), the charge gradient is enhanced by 
14 highly conserved aromatic residues which modulate the dielectric constant of the 
acidic residues local environment (22).  
Once ACh has bound to the low affinity peripheral binding site its 2D diffusion 




acidic residues and its interaction with certain aromatic residues. The combination 
of these two factors bring it into close proximity to the active site serine where it is 
hydrolysed (23)(24). The acetyl and choline groups then diffuse out of the active site 
gorge leaving the enzyme ready to hydrolyse another acetylcholine molecule (25). 
The active site of AChE is made up of a catalytic triad which is similar to that of other 
serine hydrolases. Although the AChE catalytic triad does differ in two ways, firstly 
the triad in AChE is made up of a serine, histidine and glutamic acid, whereas in other 
serine hydrolases the glutamic acid is replaced with an aspartic acid. Secondly the 
handedness of the catalytic triad is reversed in AChE (26). The positioning of the 
residues that interact with ACh during catalysis are shown in Figure 6. The NH groups 
of Gly 121, Gly 122 and Ala 204 are found in close proximity to the catalytic triad, 
these form the oxyanion hole which stabilises the serine ACh intermediate by 
forming hydrogen bonds with the acyl group of ACh. The side chains of Glu 202, Trp 
86 and Tyr 337 form the anionic binding site which interact with the choline moiety 
of ACh to  ensure the correct positioning of the substrate for catalysis (27). Once the 
ACh molecule is at the catalytic triad and stabilised by the oxyanion hole and anionic 
binding site, His 447 deprotonates Ser 203 which causes the nucleophilic attack of 
the ACh carbonyl, the choline moiety accepts a proton from His 447 and breaks off 
from the acyl group. His 447 then deprotonates a water molecule creating a hydroxyl 
ion which reacts with the acetylated Ser 203 to produce acetic acid and a 
regenerated enzyme (18), this process is illustrated in Figure 7. The action of Glu 334 
in the process is not fully understood but it is generally thought that it acts to stabilise 
the transition state by forming a hydrogen bond with either the acyl group  (28) or 






Figure 4. (A) Cross section of a cartoon representation of the crystal structure of human AChE-S 
subunit. The active site serine which covalently interacts with ACh is coloured pink and the residues 
of the peripheral anionic site are coloured orange. The approximate outline of the gorge is shown 
in black and an arrow points to the opening. (B) The same model from a different view to highlight 





Figure 5. The AChE residues that form the peripheral anionic binding site (orange) located at the 
opening of the active site gorge (Figure 4 B) and the negatively charged residues (red) that attract 
the ACh molecule to the active site cysteine (pink) at the base of the gorge. Glu 74 can also be 
considered as part of the peripheral anionic site but is coloured red due to its negative charge 
(24)(30). The approximate outline of the gorge is shown in black and a rising wedge is included to 






Figure 6. The arrangement of residues important to the catalytic activity of AChE. The catalytic triad 
is coloured pink, the oxyanion hole is coloured green and the blue residues form the anionic binding 
site. Arrows indicate the movement of H+ ions between the catalytic triad during catalysis. This 








Figure 7. The reaction mechanism of AChE catalysing the breakdown of ACh. Blue represents the 
acyl moiety, pink represents the choline moiety and a red bond indicates that it is being broken in 
the reaction step. This figure is an altered version of a figure in reference (27). 
1.1.3 AChE relevance to disease. 
AChE has been shown to have relevance to several diseases. For instance, the 
upregulation of AChE-R expression in response to certain stresses mentioned in 1.1.1 
has been shown to be detrimental to head injured mice, the inhibition of AChE-R 
overexpression with AChE-R antisense mRNA injections increased the survivability 
and lessened the drop in long term cognitive function in the head injured mice (31). 
Interestingly AChE-R has also been shown to be upregulated in the brains of people 
suffering from Alzheimer’s disease (32). The mechanism that AChE-R plays in these 
conditions is poorly understood but these studies indicate that AChE-R further study 
as it could result in better treatments for these conditions. 
AChE-S is linked to Alzheimer’s disease in two ways. Alzheimer’s disease is partly 
characterised by the loss of cholinergic neurones in the brain, this has led several 
reversible inhibitors of AChE to be developed to combat the symptoms. The rationale 
behind this method is that by inhibiting AChE the stimulation of cholinergic neurons 
can be prolonged by slowing the breakdown rate of ACh in the synapses. This can 
partially offset the reduction in cholinergic neuron activity seen in Alzheimer’s 




alleviate the symptoms in mild to moderate cases of the disease (33). AChE also 
interacts with β-amyloid plaques which along with neurofibrillary tangles, are 
thought to be the causal agent of the neurodegeneration seen in Alzheimer’s disease 
(34). The association of AChE with β-amyloid has been shown to speed up the 
formation of β-amyloid plaques which increases the rate of cognitive decline. 
Inhibitors targeting the peripheral anionic binding site of AChE were shown to slow 
the formation of β-amyloid plaques, however, inhibitors that only affected the 
catalytic triad of AChE showed no effect on the rate of plaque formation (35). This 
indicated that the peripheral anionic site may have a chaperone function for the 
formation of β-amyloid plaques, which opens the possibility that inhibitors of the 
interaction between AChE and β-amyloid can be produced to prevent or at least slow 
the onset of Alzheimer’s disease. However, more research is needed to study the off-
target effect of inhibiting the peripheral anionic site of AChE.  
BChE has also been shown to have relevance to certain diseases. It was shown that 
when BChE was inhibited plasma concentrations of very low density lipoproteins and 
triglycerides decreased, indicating that it might function in the metabolism of these 
compounds (36). Concentration of BChE in the brain increase with age and are 
elevated further in people with Alzheimer's disease (37). BChE has also been found 
to associate with the plaques that cause Alzheimer’s disease (38) indicating, that like 
AChE, BChE might play a role in the formation of the plaques. This means that BChE 
could potentially be a drug target for the treatment of Alzheimer’s disease.  
Cholinesterases have potential applications in protection against certain types of 
chemical warfare agents. If mice were given intravenous injection of BChE they could 
survive higher doses of the organophosphate (OP) chemical warfare agent soman 
(39) which irreversibly inhibits cholinesterase. The increased concentration of BChE 
in the blood stream of the mice will be irreversibly inhibited by soman which reduces 
the physiological concentration of the OP so less is available to inhibit AChE at the 
neuromuscular junction. Injections of recombinant BChE or AChE have the potential 
to be medically useful by removing OPs from people intoxicated by these compounds 
and as a pre-treatment to people entering situations that entail a high probability of 




1.2 AChE inhibiting molecules. 
1.2.1 AChE inhibiting insecticides.  
AChE is an industrially important enzyme as it is the target for OP and carbamate 
insecticides (40). these types of insecticides are the most commonly used in 
agriculture and the domestic setting (41) meaning information on their interaction 
with AChE is of high importance in assessing the threat they pose to health and, 
developing antidotes to poisoning by these compounds. The mechanism of their 
inhibition of AChE is shown in Figure 8.  
Until the 70s, the most commonly used pesticides were organochlorides, with 
Dichlorodiphenyltrichloroethane (DDT) being the most wildly used. It proved very 
effective at controlling insect populations and had low acute toxicity. However, its 
long environmental half-life (up to 15 years), accumulation in adipose tissue and link 
to cancer has persuaded the vast majority of countries to ban its use (42). This led to 
an increase in the use and development of carbamates and OP insecticides. The half-
lives of these compounds are in the range of tens of days (43) meaning they have a 
much lower long term environmental impact compared to DDT and, because of their 
relatively high reactivities, bioaccumulation isn’t seen. One negative trait that is 
shared by both DDT and the AChE inhibiting insecticides is their toxicity to bees 
(44)(45). A selection of AChE inhibiting insecticides (pirimiphos-methyl, malathion 
and pirimicarb) were tested against cabbage aphids and the species of wasp 
(Diaeretiella rapae) that parasitizes them  (46). It was found that the relative 
toxicities of the insecticides for each species differed (Table 1), with pirimicarb being 
the most toxic insecticide to the aphid but least toxic to the wasp. This highlights the 
potential for AChE inhibiting insecticides to be developed that have a high toxicity to 
a few specific pest insects while having limited toxicity to beneficial insects, but 
further work is required to confirm if this is possible.  
The major downside of AChE inhibiting insecticides is their toxicity to mammals. The 




oral LD50 in rats for the OP insecticides show a wide range, the values for Malathion, 
Ethion and Parathion-methyl are 619, 25.9 and 2.45 mg/kg respectively (48).  
 
Figure 8. A shows a schematic of an OP reacting with the active site serine of AChE, X represents the 
leaving group R1 and R2 can be any other chemical group and the O which has a double bond to the 
P is sometimes replaced with an S. B is a schematic of a carbamate reacting with the active site 
serine of AChE. R1, R2 and R3 can be any other chemical group. 
 
Table 1. The relative toxicities of two OPs (malathion and pirimiphos-methyl) and one carbamate 
(pirimicarb) to cabbage aphids and the species of wasp (Diaeretiella rapae) that parasitizes them. 
Data taken from reference (46).  
Relative toxicity Aphid Wasp 
High pirimicarb pirimiphos-methyl 
 pirimiphos-methyl malathion 
Low malathion pirimicarb 
 
For a pesticide to be registered in Britain the manufacturers must carry out a series 




without any observable side-effects developing. The maximum doses that can be 
tolerated through inhalation and skin contact also need to be known to inform on 
the threat posed to agricultural workers. The maximum safe dose values are then 
decreased by a safety margin of 10-100 fold depending on the quality of the data. If 
the concentration needed to effectively control the target insect is likely to cause 
exposure to either the consumer or farm workers that exceeds the maximum safe 
dose then the application is rejected. The environmental impact of the pesticide is 
also considered, such as it’s off target toxicity and environmental persistence (49). 
As these regulations came into place some of the more toxic OPs like parathion were 
banned (50). However, these regulations aren’t  global which means certain parts of 
the developing world, such as Nepal, still use the more toxic insecticides where they 
cause sporadic poisoning of rural workers by either accidental exposure or suicide 
attempt (51). This highlights the need for more research into AChE so insecticides 
can be developed that target any specific changes seen in the AChE of pest insects. 
One commonly proposed solution to the negative health and environmental impact 
of insecticides is to prohibit their use and rely on organic farming methods, however, 
it was shown that halving the amount of insecticide used on a wheat crop reduced 
the final crop yield by around 15% (52) and the reduction in crop yield caused by a 
100% drop in pesticide use has been estimated to range from 26-80% depending on 
the crop (53). Insecticides have also been used to save lives by controlling the 
populations of disease carrying insects. DDT alone is thought to have prevented 
around 700 million cases of malaria in Africa (54). On average people infected with 
malaria have a 1.8% chance of dying from the disease (55) meaning over its lifetime 
DDT has saved approximately 12.6 million lives. This calculation doesn’t consider 
other insecticides, continents or diseases. Although insecticides have negative 
effects on the environment and public health, stopping their use would likely result 
in large scale habitat destruction to make up for the reduced yield in agricultural 
crops and an increase in deaths from insect borne diseases. This highlights the need 






1.2.2 OPs as chemical warfare agents.  
Highly toxic OPs have been used as chemical warfare agents meaning AChE is also of 
interest to the defence sector. The first chemical warfare agent OP was developed in 
Nazi Germany as an insecticide. Its potential for weaponisation was quickly realised 
and within a few years several new OP chemical warfare agents were developed. 
These OPs were named the G series agents as they were all first made in Germany, 
and some of their structures are shown in Figure 9 A. By the start of the 1950s, British 
chemists had designed a new generation of OP chemical warfare agents called the V 
series agents (Figure 9 B), these were more toxic than the G series agents, had lower 
volatility and were more environmentally persistent (56). The LD50s of some OP 
chemical warfare agents are shown in Table 2. The 1950s also saw a third wave of 
OP chemical warfare agent development which took place in America and aimed to 
develop the V and G series agents as binary weapons. These would mix two non or 
mildly toxic chemicals in a warhead to produce the chemical warfare agent, ideally 
after firing the munition. Binary weapons greatly reduce the risk associated with the 
storage and handling of chemical warfare agent munitions.  
All countries apart from Israel, Egypt, South Sudan and North Korea have signed up 
to the 1997 CWC which prohibits the production, stockpiling, development, transfer 
and use of all chemicals listed by the convention. All signatory countries also agreed 
to destroy all pre-existing stockpiles of chemical warfare agents and their pre cursors. 
Chemicals are considered on a case by case basis for inclusion in the CWC based on 
the following factors, the toxicity of the chemical, structural similarity to chemicals 
already included, the likelihood the chemical can be used as a precursor to a chemical 
warfare agent and historical uses of the chemical as a weapon or as a precursor to a 
weapon. Chemicals included in the CWC are separated into three “schedules”, 
schedule 1 chemicals have no use other than as weapons or pre cursors to weapons, 
schedule 2 chemicals can have some legitimate uses such as in medicine or research 
and schedule 3 chemicals are produced in large quantities for commercial uses. For 
schedule 2 and 3 chemicals only their implementation or development as weapons 




A range of OP pesticides are given in Figure 9 D and, when compared to the 
structures of OP chemical warfare agents in Figure 9 A and B several structural 
differences are clear. Firstly, the insecticides include compounds with a P=S instead 
of a P=O. This is due to the fact that OPs with a P=S are relatively weak inhibitors of 
AChE so have toxicities around 100 times lower than their P=O counterparts (58)(59). 
This is presumably because O is more electronegative than S meaning the O in P=O 
attracts electrons away from P giving it a more positive charge than an S would, 
making it more susceptible to nucleophilic attack by the Ser 204 of AChE, meaning 
P=O containing molecules would inhibit AChE at a faster rate than P=S containing 
molecules. P=S containing compounds need to be activated to become toxic, this is 
done by the oxidation of the P=S to P=O by cytochrome P450 in the human liver (60) 
and all tissues of insects (61). OP detoxifying enzyme, such as paraoxonase, 
phosphotriesterase, carboxylesterase and glutathione-S-transferase are more 
prevalent in mammals than in insects (62). This means that OPs are broken down at 
a faster rate in mammals than in insects, so in insects P=S containing insecticides are 
likely to be converted to the toxic P=O form whereas in mammals they’re likely to be 
broken down before this conversion happens. This gives P=S containing insecticides 
a selective toxicity to insects. Interestingly, several insecticide resistance 
mechanisms have been attributed to upregulation of these enzymes in insects. For 
instance upregulation of glutathione-S-transferase-3 in PIuteIIa xylostella was shown 
to confer resistance to methyl-parathion (63), and upregulation of a 
carboxylesterase was shown to give Lucilia cuprina resistance to malathion (64). The 
other main difference seen between OP insecticides and chemical warfare agents is 
that the chemical warfare agents routinely have a methyl group directly bound to 
the phosphorus, this is not seen in any commonly used insecticide (40). It has been 
noted that in general, OPs that have a methyl as their R2 group (Figure 8 A) inhibit 





Figure 9. (A) Structures of some G series nerve agents, both their common and two letter NATO 
names are given. (B) Structures of some V series nerve agents. (C) Suggested but unconfirmed 






Table 2. Toxicity of some commonly studied OP chemical warfare agents as the LD50 of intravenously 
administered agents in mice. The LD50 values were taken from (56). The two letter NATO designated 
name of the G series agents are given in brackets. 
OP chemical warfare agent name Intravenous LD50 in mice (µg/kg) 
Soman (GD) 38 
Sarin (GB) 41 






















1.3 Assessment and treatment of OP poisoning 
1.3.1 Treatment of OP poisoning. 
The main cause of death in patients with acute OP poisoning is asphyxiation caused 
by overstimulation of respiratory muscles, for this reason the first step in treating OP 
poisoning is to ensure the airways are open and to administer oxygen. A competitive 
inhibitor of ACh receptors is then administered to the patient to reduce the 
overstimulation of muscles caused by the excess ACh in the synapses. The most 
commonly used inhibitor of ACh receptors is atropine (Figure 10) which is a potent 
toxin if given to people not poisoned by OPs as, it desensitises the neuromuscular 
tissue to ACh preventing muscle contraction (67). However, as this has the opposite 
effect to OPs, atropine can counteract some of the dangerous effects of OP poisoning 
(68).  
Oximes (Figure 10) can be effective reactivators of AChE inhibited with certain OPs. 
They function through a pin pong mechanism in that the AChE must first be inhibited 
by an OP after which an oxime can bind and reactivate the AChE. But some OPs show 
a high resistance to reactivation and the ability of the oxime to reactivate AChE is 
also dependent on the OP it is inhibited with. For instance, different homologues of 
tabun were shown to have a high variability in their reactivation times and the 
optimal oxime to reactivate with also differed (69). Consequently, there is no 
universal oxime which would serve as an effective treatment for all types of OP 
poisoning. Another factor that complicates treatment with oximes is that OP 
inhibited AChE can undergo a de-alkylation reaction which leaves the phosphate 
adduct with a negative charge, this process is referred to as ageing and is shown in 
Figure 11.  
Oximes have a negative charge so function through a nucleophilic attack on the 
phosphorus atom, if the phosphate adduct becomes negatively charged it will repel 
the oxime meaning no reactivation can take place (70). Although the reactivation 
kinetics of different oxime OP pairs are well studied in vitro (69)(65)(71), well 




universally accepted procedure for oxime treatment of OP poisoned patients. 
Reviews of case studies usually conclude that the available data contains too many 
uncontrolled variables to definitively say if oxime treatment is effective but, due to 
in vitro studies showing oximes can be effective against certain OPs, it is better to 
administer the oxime than not (68)(72).  
 
 
Figure 10. Structures of atropine and, the oxime functional group. These are the two drugs usually 
given to treat OP poisoning. 
 
Figure 11. Schematic of the ageing process of the OP adducts bound to the active site serine of AChE, 
this process results in an OP AChE conjugate that can’t be reactivated. 
The three main factors affecting an OPs susceptibility to reactivation are ageing rate, 
electronegativity of the phosphorus atom and the size of the phosphate adduct (73). 
Some data has also shown that after inhibition with an OP, the active site gorge of 
AChE undergoes structural changes (74). These structural changes could also affect 
the ability of an oxime to reactivate an OP inhibited enzyme.  




Many current methods for assessing the toxicity of OPs rely on exposing animals to 
them and measuring the dose that results in the death of 50% of the tested animals, 
this gives the lethal dose (LD50) values. A variety of different animals have been used 
in toxicity studies including rats (75), guinea pigs (76), mice, rabbits (77) and non-
human primates (78). Guinea pigs and non - human primates are the preferred 
animals to use in toxicity studies as their plasma levels of OP degrading enzymes such 
as BChE and carboxylesterase are more similar to humans than the other model 
organisms (79).  
For the foreseeable future, animals are likely to remain indispensable in the process 
of OP toxicity determination. However, protocols that approximate toxicity by 
studying the interactions of currently available OPs with AChE and correlating these 
results with those of animal toxicity experiments could have a value in reducing the 
number of animal experiments needed. For example, if currently available OPs with 
a high toxicity routinely produced a particular set of results in an in vitro assay, new 
OPs that produced the same or similar result could potentially be toxic. If this in vitro 
assay could (with reasonable accuracy) indicate a new OPs toxicity was several orders 
of magnitude lower than that of organophosphorus chemical warfare agents then, it 
could be safely assumed that the new OP didn’t pose a threat as a chemical warfare 
agent and no animal experiment would be needed. However, if the assay indicated 
a toxicity value close to or higher than organophosphorus chemical warfare agents, 
then animal experiments would be needed to more accurately assess the threat 
posed by the OP. Similarly assays that produced results which correlate with the 
effectiveness of prophylactic or reactivating compounds could be useful in 
identifying compounds unlikely to be more effective than the current 
countermeasures. This would prevent unnecessary animal experiments from being 
carried out on compounds that pose little threat and have no medical use. The 
success of this approach would be dependent on the degree to which the parameters 
measured by the in vitro assay correlated with the toxicity or medical usefulness of 
the compound.  
The “Animals (Scientific Procedures) Act 1986” that regulates animal experiments in 




used for experimentation and that appropriately skilled people are employed to be 
accountable for each of these requirements. This ensures the distress and suffering 
the animals are exposed to is minimised but greatly increases the cost of using 
animals in scientific experiments. So assays that can be used to reduce the amount 
of animal experiments needed in OP threat detection and countermeasure 
development would lower the cost of these procedures and improve animal welfare. 
1.3.3 Project aims. 
An engineered isoform of human AChE (AChE-d) was created using a computational 
algorithm. The algorithm used a multiple sequence alignment of wild type human 
AChE-S against “several dozen” naturally occurring homologue sequences, for each 
residue in the wild type sequence the likelihood of it being mutated to each of the 
other 19 residues in the homologues sequences was calculated. The theory being 
that mutations that are more common in nature are less likely to have negative 
effects on the enzyme as they haven’t been selected against by evolution. Any 
mutations that occurred in residues within 8 Å of the active site gorge were 
discarded. Rosetta computational mutation scanning was applied to each of the 
mutations deemed “likely” to occur in nature. For this a protein data bank structure 
of wild type human AChE-S was used. The energy difference between the wild type 
structure and the one containing the mutation was calculated, this was repeated for 
each of the mutations and the ones that reduced the activity below a certain 
threshold were selected. The threshold for a mutations likelihood to occur in nature 
and the reduction in structural energy were both altered to produce five variants of 
AChE-d, each containing a different set of mutations. The soluble expression yield, 
catalytic activity, and thermal stability of each variant were measured. The variant 
showing the highest thermal stability and expression yield whilst having the least 
change to the catalytic activity was chosen. The chosen variant (AChE-d) contained 
51 mutations (Figure 12)(80). The catalytic activity was reported to be 11.4% lower 
in AChE-d than the wild type indicating success at minimising the effect on enzymatic 
activity. Table 3 shows the percentage similarity between AChE from different 
sources and Figure 13 shows the multiple sequence alignment used to generate 




similarity between human and electric ray AChE (61.6%) but slightly lower than 
human and guinea pig (92.4%). AChE from guinea pig (81), rat (82) and electric eel 
(83) are routinely studied. So while AChE-d is not completely comparable to wild type 
human AChE, its sequence homology and similar activity indicate that it is likely to 
provide data that’s representative of wild type human AChE. For this reason, AChE-
d was chosen for further study in this project. 
The principle aims of this project were to: 
1. Test the AChE-d construct and optimise its overexpression and purification. 
 
2. Develop NMR methods to study the interactions of AChE with a range of OPs, 
and to develop protocols for use in assessing the threat of any newly 
discovered OPs.  
 
3. To gain data on the mechanism of inhibition and reactivation that could be 
used to understand whether inhibition of AChE by certain OPs causes 
structural changes in the protein that could lower the affinity of certain oximes 
for that particular OP AChE conjugate. This would help to explain the 
differential reactivation rates that oximes have for different OP AChE 
conjugates. 
Ligand observe studies using STD and CPMG experiments can be done with non-
isotopically labelled AChE purified from a natural source, but to get NMR data on 
structural changes in AChE after inhibition with an OP, isotopically labelled 





Figure 12. A comparison of the protein sequences of wild type AChE and AChE-d. The wild type 
sequence is shown in black and the mutated residues are shown in red. The secondary structure of 
wild type AChE is shown alongside the sequence and a key to the figure is included at the bottom 







Table 3. Shows the percent similarity between AChE protein sequences from different sources. The 
signal sequences and the last intron containing the cysteine that forms an inter subunit disulphide 
bond were removed from sequences as they were not present in the AChE-d protein. Clustal omega 
was used for the sequence alignment. 
Source of AChE Electric eel Rat AChE-d Human Guinea pig 
Electric eel 100.00 62.29 63.77 61.55 62.11 
Rat 62.29 100.00 83.39 88.69 90.69 
AChE-d 63.77 83.39 100.00 90.71 85.25 
Human 61.55 88.69 90.71 100.00 92.35 







Figure 13. Multiple sequence alignment of AChE-S from different sources. Residues are colour coded 
based on their physical properties. Red are hydrophobic, blue are negatively charged, pink are 
positively charged and green polar. Residues marked with a * are conserved in all sequences and – 




Chapter 2. Optimisation of the expression and 
purification of a designed isoform of 
acetylcholinesterase. 
2.1 Introduction 
2.1.1 Recombinant expression of AChE. 
E. coli was the expression system of choice for this project because of the low cost 
and relative simplicity of the protocol compared to expression in more complex cells 
(84). Isotopic labelling of recombinant proteins is also much cheaper in E. coli due to 
the simplicity of the growth media needed. This makes it the ideal expression system 
for proteins to be used in NMR experiments (85). Unfortunately, human AChE is a 62 
kDa protein containing three intra chain disulphide bonds and one inter chain 
disulphide bond (UniProtKB - P22303 (ACES_HUMAN)). For this reason attempts to 
express it in E. coli have had very limited success. Previous attempts to express AChE 
in E. coli resulted in the production of insoluble inclusion bodies (86). Attempts to 
refold the inclusion bodies produced only 4.15 mg of active protein from 750 L of 
media (87). Expression of the protein in other cell types has had more success. No 
exact figure for the recombinant expression yield of AChE in mammalian cells could 
be found, but usable quantities of AChE suitable for kinetic experiments have been 
expressed in HEK293 cells (88)(89). Active AChE (0.5 – 3.7 mg/l) was produced using 
the Baculovirus expression system in sf9 insect cells (90). AChE has been 
recombinantly produced in tobacco plants with yields of around 700 – 900 mg/kg, 8 
– 10 weeks were needed to produce AChE by this method (91) making it relatively 
time consuming. 
2.1.2 Ellmans assay. 
The use of 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) and acetylthiocholine (ATCh) 
to assess the activity of AChE was first described in reference (136) and the technique 




reactions that take place in the Ellman’s assay are shown in Figure 14. AChE catalyses 
the hydrolysis of ATCh to acetic acid and thiocholine which then reacts with DTNB, 
one of the products of this reaction is 5-mercapto-2-nitrobenzoic acid (5M2NA) 
which has a yellow colour. The A412 can be used to measure the concentration of 
5M2NA and because one 5M2NA is released for every ATCh that is hydrolysed, the 
A412 is an indirect measure of how much ATCh has been hydrolysed. 
 
Figure 14. Schematic for the two chemical reactions that are coupled by the Ellman’s assay. (A) Is 
the AChE catalysed hydrolysis of ATCh which releases acetic acid and thiocholine as products. (B) Is 
the reaction between thiocholine and DTNB which produces 2-(3-carboxy-4-nitrophenyl)-N,N,N-
trimethylethan-1-aminium and 5M2NA which has a yellow colour.  
The Ellman’s assay has been used to study AChE in a variety of ways; including its use 
in combination with site directed mutagenesis to identify the amino acid residues 
that are important for catalytic activity (137) and to identify the mutations in 
mosquito AChE that confer resistance to certain insecticides (138). This assay has 
also been used to study the inhibition of AChE (139) and the effectiveness of oxime 
reactivators that are used to treat poisoning with these inhibitors (140).  
 
2.1.3 Uniform 15N labelling in different cell types. 
Although insect and mammalian cells can produce active AChE, uniformly labelling 
the expressed protein with 15N requires expensive media containing multiple 15N 
labelled organic compounds (92)(93). Labelling media can be purchased from 
Cambridge Isotope Laboratories, the costs are around £5000/l and £5500/l for insect 
and mammalian cells respectively.  Media used to uniformly label an E. coli expressed 




NH4Cl which costs around £13 a gram is the most expensive part of the media. It was 
for these reasons that an E. coli expression system was desired over other cell lines. 
2.1.4 Designed isoform of AChE. 
It was reported that a designed isoform of human AChE containing 51 mutations and 
a thioredoxin (TRX) fusion partner could be expressed in SHuffle® E. coli and the 
mutations in the gene had a minimal effect on the kinetic parameters of the enzyme 
(80). Shuffle E. coli was specifically developed to express disulphide bonded proteins 
by reducing the activity of the cytoplasmic reductive pathway and  adding a 
disulphide bond isomerase to the cytoplasm (94). It was decided that the expression, 
purification and isotope labelling of this isoform (AChE-d) should be investigated. In 
(80) AChE was one of many proteins chosen for its lack of soluble expression in E. 
coli. The aim of the paper was to use a computer program to predict mutations that 
should be made to increase soluble expression and have minimal effect on activity. 
The optimal expression conditions and vector were not investigated. We intended to 
use heteronuclear multiple quantum coherence-selective optimized flip angle short 
transient (HMQC-SOFAST) NMR experiments for this work. Samples needed to be 
roughly 320 µl for a 5 mm Shigemi tube and over 25 µM so large amounts of protein 
are needed (roughly 0.5 mg of labelled AChE per sample) which made the 










2.2 Materials and methods 
2.2.1 Transformation and glycerol stock production. 
Competent Shuffle express T7 E. coli were purchased from New England bio labs, the 
pET-32b vector containing AChE-d-TRX was kindly provided by Dr Sarel Fleishman. 
All other AChE-d constructs were made following the procedure described in section 
2.2.8.  
Plasmid (10 ng) was mixed with 50 µl of competent shuffle E. coli in a sterile 1.5 ml   
Eppendorf tube. This was left on ice for 10 minutes then heat shocked at 42oC for 45 
s in a temperature controlled water bath then left on ice for another 5 min. 150 µl of 
sterile 2YT media (16 g/l tryptone, 10 g/l yeast extract, 5 g/l NaCl) was added, the 
Eppendorf containing the transformation media was then placed in a shaking 
incubator at 37oC 180 rpm for 1 h. After incubation the mixture was spread on LB 
agar plates containing ampicillin at 100 µg/ml these were then placed in an incubator 
at 37oC for roughly 19 hours. 
Single colonies were used to inoculate four 50 ml cultures of 2YT media containing 
100 µg/ml ampicillin in 250 ml conical flasks which were incubated at 37oC in a 
shaking incubator at 180 rpm until the OD600 was around 0.6. To create glycerol 
stocks, 840 µl of culture was transferred to cryo vials and 160 µl of sterile 50% 
glycerol, 50% water was added, these were then flash frozen in liquid nitrogen and 
kept on dry ice. The remaining cell cultures were induced with IPTG and placed back 
in the incubator for 3 hours. After this the cells were lysed using the protocol 
described below, and the AChE-d activity was measured. The glycerol stock that 
came from the culture with the highest AChE-d activity was kept at -80oC and the 
others were discarded. 
2.2.2 Protein expression. 
2YT media was used to grow E. coli for unlabelled expression. Ampicillin (100 µg/ml) 
was added so only E. coli harbouring the expression plasmid would grow. Test 




Large growths that were intended to produce protein for kinetic or NMR experiments 
were carried out in 2.5 L baffled conical flasks containing 1 L of media. 
The glycerol stock of the desired transformant was streaked on LB agar containing 
100 µg/ml ampicillin and incubated at 37oC for 17 hours. Starter cultures of 2YT 
media were inoculated and incubated at 30oC with shaking at 180 rpm for 17 hours. 
Starter cultures were then centrifuged at 3220 g for 20 minutes at 4oC, the 
supernatant was discarded, and the pellet was re-suspended in 2 ml of fresh 2YT 
media for each 50 ml starter culture, the OD600 of this was then taken. The volume 
of concentrated starter culture needed to inoculate the main cultures to an OD600 of 
0.2 was calculated (usually around 2.5 ml per L of main culture). After inoculation 
cultures were incubated at 37oC with shaking at 180 rpm until OD600 reached 0.4 
(around 1.5 hours) at which point the temperature was dropped to 25oC and 
incubation was continued until OD600 was between 0.6 and 0.8 (around 1 hour). 
Protein expression was then induced by adding IPTG to a final concentration of 0.45 
mM and cultures were returned to the incubator and left over night. The next day 
cultures were centrifuged at 3220 g for 20 minutes at 4oC, the supernatant was 
discarded and the pellet was re-suspended in 10 ml lysis buffer (20 mM sodium 
phosphate, 100 mM NaCl, pH 7.3) for every litre of cell culture. Once cells were re-
suspended in lysis buffer they could either be frozen at -20oC or lysed. 
 
2.2.3 Cell lysis. 
Once cells were re-suspended in lysis buffer, Triton X-100 and lysozyme were added 
to a final concentration of 0.1 % v/v and 0.1 mg/ml respectively. After 20 minute 
incubation at room temperature, MgCl2 and Bovine DNase 1 were added to final 
concentrations of 5 mM and 20 µg/ml respectively, this mixture was then incubated 
at room temperature until viscosity reduced. The mixture was then sonicated at 
amplitude of 15 microns for 3 minutes with a 10 second on/off cycle. The lysate was 
centrifuged at 20,000 g for 20 minute at 4oC. The lysate supernatant was passed 
through a 0.45 µm syringe filter and the lysate pellet was re-suspended in a volume 





2.2.4 Ni affinity, Procainamide affinity and size exclusion chromatography. 
The buffers used in Ni affinity chromatography were all made in Milli-Q water, they 
were; 
 
1. Charging buffer: 0.2 M NiSO4  
 
2. Sodium acetate buffer: 20 mM sodium acetate, 0.5 M NaCl, pH 4 
 
3. Lysis buffer: 20 mM sodium phosphate, 100 mM NaCl, pH 7.3 
 
4. Wash buffer: 20 mM sodium phosphate, 100 mM NaCl, 50 mM imidazole, pH 7.3 
(unless otherwise stated) 
 
5. Strip buffer: 20 mM sodium phosphate, 100 mM NaCl, 20 mM ethylenediaminetetra 
acetic acid (EDTA), pH 7.3 
 
A Ni column was made using 2 ml of chelating Sepharose fast flow in a 20 ml Bio-Rad 
gravity flow column. First the column was washed with 10 column volumes (cv) of 
Milli-Q water followed by 2 cv of charging buffer (buffer 1), then 3 cv sodium acetate 
buffer (buffer 2), after this the column was washed with 10 cv lysis buffer (buffer 3). 
Up to 20 ml of lysis supernatant was loaded onto the column, after it had all flowed 
through, the column was washed with 10 cv lysis buffer (buffer 3) and then 10 cv 
wash buffer (buffer 4). The protein was eluted with 10 cv strip buffer (buffer 5). After 
strip buffer (buffer 5) was added the flow through was collected in 1 ml fractions. 
The column was then washed with 10 cv Milli-Q water and stored in 20 % ethanol. 
The A280 of all strip buffer fractions was measured to identify the ones containing 
protein, these were pooled and concentrated using a 6 ml 50 kDa cut off centrifugal 
concentrator to a volume of between 1-2 ml to increase separation on the size 
exclusion column. 
 
Procainamide Sepharose purification was optimised using a batch method. 40 µl of 




Sepharose was washed by adding 1 ml of Milli-Q water then allowing to mix on a 
rotary mixer, after 5 minutes the samples were centrifuged at 4,000 g for 1 minute 
and the supernatant was removed. This was repeated with lysis buffer. 0.5 ml of 
lysate supernatant was then added to beads and allowed to mix. Samples were then 
washed again with 1 ml lysis buffer then mixed with 1 ml lysis buffer containing the 
specified concentration of NaCl. Samples of the elution were taken for analysis by 
SDS-PAGE gels and activity assays.   
 
The size exclusion column used had a cv of 260 ml and was packed with Superdex 
200. The column was equilibrated with 2 cv of lysis buffer before the 1-2 ml 
concentrated protein sample was loaded, lysis buffer was used to elute the protein. 
5 ml elution fractions were collected, samples with high A280 were analysed by SDS-
PAGE to assess purity. Samples containing only AChE-d were concentrated to around 
30 µM using a 15 ml 50 kDa cut off centrifugal concentrator.  
 
2.2.5 Ellmans assay of Lysate supernatant. 
A 100 mM stock of 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB) was made in dimethyl 
sulfoxide (DMSO). This was added to lysis buffer along with acetylthiocholine (ATCh) 
to give a final concentration of 1 mM DTNB and 2 mM ATCh. This was made up just 
before the experiment starts as the DTNB and ATCh react over time. 990 µl of the 
lysis buffer containing DTNB and ATCh was added to a 1 ml cuvette, this was used to 
blank the spectrophotometer. 10 µl of lysate supernatant was then added to the 
cuvette and mixed. The absorbance at 412 nm was taken every 2 s for 20 s using the 
kinetics mode on a Nanodrop One and an initial delay of 1 s was included as required 
by the Nanodrop. Highly concentrated lysate supernatant produced a nonlinear 
graph of absorbance vs time, when this happened the lysate supernatant was diluted 
with lysis buffer and the dilution was taken into account in the final calculation. The 








Rate = (A412t21 – A412t1) * 3 * df 
Equation 1. Used to calculate the rate of reaction of the AChE catalysed breakdown of ATCh. The 
units are absorbance units/min/10 µl lysate supernatant. A412t21 is the absorbance of the recording 
at 21 s, A412t1 is the absorbance of the recording at 1 s and df is the dilution factor. 
 
Samples eluted from procainamide Sepharose with low NaCl concentrations had low 
AChE-d activity which precluded the method described above from being used to 
measure their activities. For samples eluted in the range of 0 – 0.5 M NaCl 10 µl of 
elution was added to 990 µl of Ellmans buffer and left for 3 min at which point the 
A412 was taken. For samples eluted in the range of 0.6 – 1 M NaCl the A412 was taken 
after 20 s and extrapolated to get the value after a 3 min incubation. 
 
2.2.6 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). 
Tris SDS-PAGE gels were made using the recipe shown in Table 4. The 12.5 % 
resolving gel was made first. The 10% ammonium persulfate (AMPS) and 
tetramethylethylenediamine (TEMED) were added last as they initiate the setting of 
the gel. Empty Novex gel cassettes were filled ¾ of the way up then 200 µl of water 
saturated butanol was added to the top of the unset gel to flatten the meniscus. 
After the resolving gel had set the butanol was washed off and the rest of the gel 
cassette was filled with stacking gel. The comb was then added to the stacking gel, 
this was then left to set. 
Table 4. Composition of SDS-PAGE gels.  
Reagent 12.5 % resolving gel 5 % Stacking gel 
40 % Acrylamide 6.5 ml 1.25 ml 
1.5 M Tris pH 8.8 5 ml 0 ml 
0.5 M Tris pH 6.8 0 ml 1.25 ml 
10 % SDS 200 µl 100 µl 
H2O 8.35 ml 7.3 ml 
10 % AMPS 50 µl 50 µl 





A stock solution of 5 X loading buffer was made, this contained 0.25% Bromophenol 
blue, 0.5 M dithiothreitol (DTT), 50% Glycerol, 10% sodium dodecyl sulphate (SDS) 
and 0.25 M Tris, pH 6.8. This was diluted in the protein samples to a concentration 
of 1 X. After the loading buffer was added the samples were boiled for 2 minutes. In 
the case of pre and post induction samples, 0.5 ml of cell culture was taken and 
centrifuged at 13,000 g for 2 minutes. The supernatant was removed and 100 µl of 1 
X loading buffer was added to the pre induction pellet. The volume of 1 X buffer 
added to the post induction pellet was adjusted based on its OD600 so both pre and 
post induction samples had the same protein concentrations. The samples were then 
boiled for 2 minutes. The samples were drawn up and down a Hamilton syringe to 
shear DNA, this was done until the viscosity of the samples had reduced. Gels were 
run at 75 mV until the dye front had passed into the resolving gel then the voltage 
was increased to 180 mV until the dye front reached the end of the gel cassette. The 
running buffer used contained 3 g/l Tris, 14.4 g/l Glycine and 1 g/l SDS. Precision plus 
molecular weight marker (BioRad) was used and the molecular weight standard on 
all gels. 
 
2.2.7 Attempted refolding of AChE-d-TRX. 
Shuffle E. coli that had been transformed with a plasmid containing the gene for 
AChE-d-TRX was grown in a 100 ml culture of 2YT media in a 500 ml conical flask, the 
cells were lysed as described above. A ground glass homogeniser was used to re-
suspend the lysate pellet in 2.5 ml wash buffer which contained 50 mM Tris, 10 mM 
EDTA and 0.5 % Triton x-100 (pH 8). The sample was centrifuged at 15,000 g for 5 
minutes. This was repeated once with wash buffer then again with Milli-Q water. The 
protein concentration was estimated by running a sample on an SDS-PAGE gel along 
with samples containing known amounts of bovine serum albumin (BSA). 
The protein resuspension was then dissolved in solubilisation buffer (50 mM Tris, 5 
M guanidinium chloride (GdmCl), 11 mM DTT, pH 8.75). Enough solubilisation buffer 
was used to give a protein concentration of 2 mg/ml. This was incubated at room 




Half of the solubilised protein was added to a refolding buffer containing 50 mM Tris, 
0.05 M GdmCl, 0.78 mM GSH and 0.44 mM oxidised glutathione (GSSH) at pH 8.75. 
The other half of the solubilised protein was added to a buffer with the same 
components as above but 0.5 M GdmCl instead of 0.05 M. The volume of the 
refolding buffers was 100 X the volume of the solubilised protein being added. 
Solubilised protein was added dropwise while stirring to avoid protein precipitation 
forming. The refolding samples were incubated at room temperature for 2 hours 
then over night at 4 ⁰C whilst stirring. 
Protein precipitate was removed by centrifugation at 15,000 g for 10 minutes, the 
supernatant was dialysed in 5 L of lysis buffer overnight at 4 ⁰C and then 
concentrated with a centrifugal concentrator.   
2.2.8 Sub cloning and Polymerase chain reaction (PCR). 
The AChE-d gene was removed from the pET-32b vector using NcoI and XhoI 
restriction enzymes. The NcoI restriction site was between the TRX tag gene and the 
AChE-d gene so this released a DNA fragment containing only the AChE-d gene. This 
gene was then ligated into pET-23a using the same restriction sites. The AChE-d gene 
contained a stop codon which prevented the C terminal His tag of pET-23a being 
incorporated into the protein (Figure 15 A and B).  
A modified pET-23b plasmid that had 6 histidine codons added after the T7 promotor 
(pLWRP51)  (95) was used to produce N terminally His tagged AChE-d. PCR was used 
to copy the AChE-d gene out of the pET-23a construct, because pLWRP51 contained 
an NdeI restriction site instead of an NcoI site, the forward primer used in the PCR 
reaction contained the sequence for the NdeI site (CATATG) instead of the NcoI 
sequence (CCATGG). The NdeI and XhoI restriction sites were used to cut the AChE-
d gene and the plasmid. The AChE-d gene contained a stop codon at the C terminus 
to prevent the C terminal His tag of pLWRP51 being incorporated into the protein 
(Figure 15 D). The sequence of the primers used is shown in Table 5.  
Site directed mutagenesis to remove the stop codon from AChE-d was performed to 
allow the incorporation of the C terminal His tag in pET-23b (Figure 15 C). The primers 




the AChE-d gene but the stop codon “TAA” was omitted from the primer. NdeI and 
XhoI were used to cut the ends of the PCR product which was then ligated into pET-
23b that had been cut with the same restriction enzymes.  
Phusion high fidelity DNA polymerase was used for all PCR reactions. All constructs 
were sequenced between the T7 promoter and T7 terminator sequence to ensure 
no mutations had occurred in the AChE-d gene. 
The PCR conditions used were 30 cycles of 1 min at 94oC for denaturation 2 min at 
55oC for primer annealing and 3 min at 72oC for extension. 
Table 5. Primers used to produce the AChE-d genes with a C terminal His tag (AChE-d C His) and N 
terminal His tag (AChE-d N His). pET-23a containing the AChE-d gene was used as the template in 
both PCR reactions. 
AChE-d 
construct 















Figure 15. A cartoon representation of different AChE-d gene constructs. (A) AChE-d in pET-32b, this 
construct produced AChE-d TRX. (B)  AChE-d in pET-23a, this construct produced AChE-d without a 
His tag. (C) AChE-d in pET-23b, this construct produced AChE-d with a C terminal His tag. (D) AChE-





2.3.1 Optimisation of the expression and purification of AChE-d-TRX. 
Temperature and point of induction were both optimised to give the highest yield of 
soluble AChE-d-TRX expression by shuffle E. coli. Recombinant expression of the 
protein was induced by addition of IPTG to the liquid cultures to a final concentration 
of 0.45 mM. The expression yields were compared using the Ellmans assay to 
measure the AChE-d activity in the lysate supernatant of each culture. First the 
optimal temperature of induction was investigated. The results are shown in Table 
6. All cultures were induced at around an OD600 of 0.6. Cultures induced at 18 and 
25oC were induced overnight, cultures at 30 and 37oC were induced for 4 hours.  
Table 6. Effect of induction temperature on AChE-d-TRX yield.  







The optimal OD600 to induce expression of the protein was tested next. The cultures 
were induced at 25oC overnight as the data in Table 6 indicated this would give 
maximum recombinant protein yield, the results are shown in Table 7. 
Table 7. Effect of OD600 at induction on AChE-d-TRX yield.  










The data showed that the optimal OD600 to induce at was between 0.6 and 0.8. From 
this point on all cultures were induced between an OD600 of 0.6 and 0.8 at 25oC 
overnight.  
The protein contents of Shuffle E. coli expressing AChE-d-TRX can be seen in Figure 
16. The mass of the AChE-d-TRX construct is 75.834 kDa. A band at the expected 
mass appears in the post induction lane but not the pre induction lane. The same 
band can be seen in the lysate pellet but not the lysate supernatant. This indicates 







Figure 16. SDS-PAGE analysis of samples taken from a 50 ml growth of Shuffle E. coli expressing 
AChE-d-TRX. Samples prepared as described in 2.2.6. The red arrow shows the location of AChE-d-
TRX.  
2.3.2 AChE-d-TRXTRX refolding. 
In order to investigate refolding of the lysate pellet, two refolding buffers were 
prepared, one with 0.05 M GdmCl and the other with 0.5 M GdmCl. The optimal 
concentration of GdmCl to use would be one that is high enough to keep proteins 




properly folded protein. This concentration was not known, which necessitated the 
use of two concentrations which would allow their effectiveness to be compared.  
The lysate pellet was washed and re-suspended in 2.5 ml Milli-Q water with a ground 
glass homogeniser. Different volumes were run on an SDS-PAGE gel with known 
concentrations of BSA. This was done to estimate the protein concentration in the 
lysate pellet suspension. This gel is shown in Figure 17.  
 
Figure 17. SDS-PAGE gel of varying volumes of AChE-d-TRX lysate pellet suspension and several 
known amounts of BSA. A red arrow marks the position of AChE-d-TRX. 
Based on Figure 17 it was estimated that the total protein concentration in the lysate 
pellet suspension was around 3 mg/ml, meaning the 2.5 ml sample contained 
approximately 7.55 mg of protein. The protein was dissolved in 3.75 ml of 
solubilisation buffer which gave a protein concentration of 2 mg/ml.  
As Figure 18 shows pellets formed in both refolding conditions, in both cases no 




unexpected due to the fact that any correctly folded AChE-d-TRX would be very 
dilute at this point in the refolding process. The supernatants of both refolding 
buffers were concentrated to roughly 0.5 ml using 15 ml 50 kDa cut off centrifugal 
concentrators. No AChE-d-TRX could be seen in the concentration supernatant lane 
for either refolding condition and no activity could be detected. This showed that all 







Figure 18. SDS-PAGE analysis of the products of refolding in two different buffers with different 
concentrations of GdmCl. Refolding pellet refers to the pellet that formed during the incubation in 
refolding buffer. Concentrated supernatants are samples taken from the spin concentrator. A red 







2.3.3 Ni affinity chromatography of AChE-d-TRX. 
The AChE-d-TRX construct contained a His tag located between the AChE-d and TRX 
subunits (Figure 1 A) so Ni affinity chromatography was attempted to purify the 
soluble AChE-d-TRX from the lysate supernatant.  
Figure 19 A shows the elution profile of AChE-d-TRX from the Ni column, a large 
proportion of the total AChE-d-TRX came off the column in the wash. Figure 19 B 
shows that even after washing the column with lysis buffer containing 40 mM 
imidazole many contaminating proteins remain in the elution, and because around 
33 % of the AChE-d-TRX was already washed off the column at this concentration of 
imidazole, increasing the concentration further would have likely resulted in the 
amount of AChE-d-TRX recovered being too low to provide us with an adequate 
supply of enzyme for kinetic and NMR experiments.  
As the affinity of AChE-d-TRX for the Ni matrix was too low for this method of 
purification to be practical, and the majority of AChE-d-TRX produced by E. coli was 
insoluble, it was decided that refolding would be attempted again. However, the TRX 
tag was removed for this second attempt. It was thought that the AChE-d and TRX 
domains could be interacting with each other during the refolding process which 
could be preventing the correct folding of both domains. The structure of this new 
construct is shown in Figure 1 B. It was assumed that more insoluble AChE-d would 
be produced after the removal of the TRX tag as the purpose of this tag is to aid in 
the solubilisation of recombinant proteins. This presumed increase in AChE-d yield 





Figure 19. (A) The elution profile of AChE-d-TRX from a Ni affinity column based on AChE-d-TRX 
activity. Fractions 1 -7 were washed with lysis buffer (blue), 8-14 were washed with lysis buffer 
containing 40 mM imidazole (red) and fractions 15-20 were eluted with lysis buffer containing 20 
mM EDTA (green). An SDS-PAGE of a selection of these samples is shown in Figure 19 B. (B) SDS-
PAGE analysis of purification fractions from the Ni affinity chromatography of AChE-d-TRX. The 
AChE-d-TRX activity of these samples is shown in Figure 19 A. Lanes labelled lysis buffer 1 and 2 
correspond to fractions 1 and 2 respectively in Figure 19 A, wash buffer 1 and 2 correspond to 
fractions 8 and 9 in Figure 19 A and Elution buffer 1 – 5 correspond to fractions 15 – 19 in Figure 19 




2.3.4 Optimisation of the expression and purification of AChE-d. 
The mass of AChE-d without the TRX tag is 62.517 kDa, in Figure 20 no clear band can 
be seen in the lysate pellet lane at this mass. 10 µl of AChE-d lysate supernatant gave 
an activity of 3.240 A412/min, whereas the same amount of lysate supernatant from 
an AChE-d-TRX growth of the same size gave an activity of 0.634 A412/min (Table 8). 
This indicated that the soluble expression had increased fivefold but the overall 
expression had dropped significantly. This is shown by the large band of AChE-d-TRX 
seen in Figure 16 compared to the lack of any visible AChE-d band seen in Figure 20.  
This AChE-d construct didn’t have a His tag so it was decided that a cholinesterase 
specific affinity purification matrix called procainamide Sepharose, the chemical 
structure of which is shown in Figure 21, should be investigated for its ability to purify 
AChE-d. Procainamide Sepharose consists of the reversible AChE inhibitor 
procainamide bound to Sepharose through an amide linkage (96). The suggested 
binding and elution buffers were a 20 mM phosphate, 100 mM NaCl buffer for 
binding and washing, then to elute with 20 mM phosphate, 1 M NaCl buffer. It was 
decided that a range of NaCl concentrations should be tested to optimise the wash 
step.  
Figure 22 shows that a large number of proteins were eluted from the procainamide 
Sepharose at all the NaCl concentrations tested between 0 and 1 M. Figure 23 shows 
the activity of each of these samples and Figure 24 shows the proteins that remained 
bound to procainamide Sepharose after elution with 1 M NaCl. This data showed that 
NaCl didn’t selectively elute AChE-d from procainamide Sepharose and even after 1 
M NaCl elution many proteins remained bound including over 50 % of the AChE-d.  
Procainamide Sepharose was deemed unsuitable for the purification of AChE-d, it 







Figure 20. SDS-PAGE gel of samples of a Shuffle E. coli growth expressing AChE-d. The soluble and 
insoluble proteins from the growth are shown as well as samples from the media before and after 
induction with IPTG. The conditions of this gel are the same as used in Figure 2.  A red arrow 






Figure 21. Chemical structure of procainamide bound to a bead of Sepharose. 
 
 
Figure 22. SDS-PAGE gel of AChE-d eluted from procainamide Sepharose in batch with varying NaCl 





Figure 23. Bar chart showing the AChE-d activity of samples eluted from procainamide Sepharose 
with varying NaCl concentrations.  Samples of lysate supernatant were incubated with 
procainamide Sepharose in batch then washed with 20 mM sodium phosphate buffer. For elution 
20 mM sodium phosphate buffer containing the concentration of NaCl indicated on the x axis was 
added. AChE-d activity was measured with the Ellman’s assay to assess the relative AChE-d 
































Figure 24. SDS-PAGE gel showing the proteins that remain bound to procainamide Sepharose after 
elution with 20 mM sodium phosphate buffer containing 1 M NaCl at pH 7.3. After the elution 40 µl 
of beads were mixed with 10 µl of 5 X sample buffer and boiled for 2 minutes, 10 µl of this was 
loaded onto the SDS-PAGE gel. 
2.3.5 Purification optimisation of His tagged AChE-d. 
Two different constructs of His tagged AChE-d were made; one had an N-terminal 
tag and the other a C-terminal tag. No active AChE-d could be produced from the 
construct with the N-terminal His tag but the C-terminally His tagged AChE-d showed 
unchanged expression when compared with the untagged AChE-d. When SDS-PAGE 




d (Figure 25) no large band could be seen at the mass of AChE-d (62.517 kDa) in any 
of the lanes. 
The AChE-d activity of the lysate supernatant was 3.887 A412/min/10 µl, whilst 
without the His tag the activity was 3.240 A412/min/10 µl (Table 8). This further 
confirmed that the addition of the tag did not greatly alter the expression yield.  
The concentration of imidazole to wash the Ni affinity column with was optimised, 
Figure 26 A shows the elution fractions of this experiment. 
 
 
Figure 25. SDS-PAGE analysis of samples of a Shuffle E. coli growth expressing AChE-d C-His. The 
lysate supernatant and pellet from the growth are shown as well as samples from the media before 




The vast majority of the bound proteins were eluted at 40 mM imidazole but some 
contaminating proteins remained bound until EDTA was used to strip the Ni from the 
column. Figure 26 B shows the AChE-d activity of the samples shown in Figure 26 A. 
It was decided that 50 mM imidazole should be used in the wash step as the vast 
majority of contaminating proteins were removed at this concentration but only 
around 4 % of the total AChE-d activity was lost. 
As Figure 26 A shows contaminating proteins were present after the wash with 50 
mM imidazole so it was decided that gel filtration should be used to try and separate 
AChE-d from the low molecular weight contaminants that remain after Ni affinity 
chromatography.  
Figure 27 shows the chromatogram from the size exclusion chromatography, 
fractions 28-35 were run on an SDS-PAGE gel shown in Figure 28 A to assess the 
purity of the elutions. Based on this gel, fractions 28-33 were concentrated, the 
purity of this sample can be seen in Figure 28 B. The A280 indicated that around 2 mg 
of AChE-d can be recovered from every litre of Shuffle E. coli in 2YT media. The 
identity of the band in figure 26 A marked by a red arrow was confirmed as AChE-d 
by in gel digestion and subsequent peptide mass fingerprinting. 
 
Table 8. AChE-d activity in 10 µl of lysate supernatant of each of the AChE-d constructs. 




AChE-d C-His 3.887 






Figure 26 A. (A) SDS-PAGE analyses of the proteins in the lysate supernatant and the proteins that 
were eluted from the Ni column by different buffers. EDTA or imidazole was added to 20 mM 
sodium phosphate buffer that contained 100 mM NaCl and pH was adjusted to 7.4. (B) AChE-d 
activity in 10µl of the samples shown in (A). This experiment was done with successive elutions with 





























Figure 28. (A) SDS-PAGE analysis of fractions taken across the major peak seen on size exclusion 
chromatography of an AChE-d sample after Ni affinity chromatography. (B) SDS-PAGE analysis of 
fractions 28-33 from (A) after concentration. 10 µg of AChE-d loaded onto gel. Red arrows mark the 






The two refolding buffers used were exactly the same apart from the concentration 
of GdmCl, the two concentrations used were 0.05 M and 0.5 M. The hope was that 
one would produce more soluble and active AChE-d-TRX than the other, conditions 
could then be slightly altered, and the amount of active AChE-d-TRX measured with 
the Ellman’s assay to assess the impact of the change in conditions on yield. This 
process would then be continued until no further gains in AChE-d-TRX refolding were 
seen. The pH, ratio of GSH to GSSH, protein concentration and GdmCl concentration 
can all affect the outcome of refolding. Because no activity was seen in either 
refolding condition, all these factors would need to be screened with no guarantee 
that any of them would produce soluble AChE-d-TRX. It was for this reason that Ni 
affinity purification of the soluble AChE-d-TRX from the lysate supernatant was 
attempted. 
2.4.2 TRX tag removal.  
In order to improve the probability of producing soluble and active AChE-d from the 
refolding experiment the TRX tag was removed. It was assumed that removing the 
TRX tag would cause E. coli to produce more insoluble and easier to refold AChE-d. 
The hypothesis was that because TRX tags have been shown to increase the yield of 
soluble recombinant protein (97)(98), removal of the tag would produce a higher 
yield of insoluble AChE-d and less soluble AChE-d. This was advantageous as only 
insoluble material can be used in refolding experiments. It has been shown that a 
fusion protein of Dihydrofolate reductase and H-Ras produced insoluble material 
after expression. Attempts to refold the inclusion bodies were unsuccessful. 
However, attempts to refold a mixture of the two un-fused proteins produced 
soluble H-Ras and Dihydrofolate reductase (99). It was thought that a similar result 
could be achieved by removing the TRX tag from AChE-d-TRX as the TRX tag could be 
interfering with the refolding. Interactions between the AChE-d and TRX subunits in 




subunits from forming, so by removing the TRX tag a source of interference in the 
refolding proses would be removed.  
As Table 8 shows the yield of active AChE-d in the lysate supernatant increased 
fivefold after the removal of the TRX tag but interestingly, the overall AChE-d 
expression dropped to a yield that couldn’t be detected in the lysate supernatant, 
lysate pellet or post induction sample by SDS-PAGE analysis (Figure 20) whereas the 
AChE-d-TRX construct had produced a large band in the lysate pellet and post 
induction samples (Figure 16). The new AChE-d construct without the TRX tag was 
expressed in BL21 E. coli, the activity in the lysate supernatant was 0.383 A412/min/10 
µl of lysate supernatant. When expressed in Shuffle the activity was 3.865 
A412/min/10 µl of lysate supernatant. No band at the correct MW could be seen in 
the lysate supernatant or pellet after SDS-PAGE analysis of the BL21 expression of 
AChE-d (data not shown). In the paper reporting the creation of AChE-d (80), wild 
type AChE-TRX was expressed in Shuffle E. coli but no activity was recovered in the 
lysate supernatant. This indicated that the combination of Shuffle and the mutations 
present in AChE-d are required to get usable quantities (> 0.5 mg/l of E. coli culture) 
of cholinesterase.  
The increase in soluble protein seen after the TRX tag removal was surprising but 
even more surprising was the disappearance of any insoluble AChE-d which could 
indicates a drop in recombinant protein production or that removal of the TRX tag 
allowed the Shuffle E. coli to produce a partially folded form of AChE-d which was 
soluble but more susceptible to proteolysis than the insoluble AChE-d-TRX. Because 
no band was seen in the lysate pellet of the BL21 expression of AChE-d the E. coli 
strain didn’t noticeably affect the amount of insoluble AChE-d produced. Further 
experiments are needed to explain the apparent drop in recombinant protein 
expression after the removal of the TRX tag. Unfortunately, the effect of reducing 
agents on AChE-d activity could not be tested because reducing agents would 
interfere with the Ellmans assay by reacting with DTNB. However, it was assumed 
that the soluble and active AChE-d expressed by Shuffle had all of its disulphide 
bonds correctly oxidised as the cytoplasm of Shuffle E. coli was designed to be more 




Other cases of protein tags having a detrimental effect on soluble expression of 
certain proteins have been published (100)(101). There is published data that shows 
TRX tags can increase overall expression but reduce soluble expression for proteins 
over 25 kDa (102). The mechanism behind this remains unclear. The AChE-d 
construct with an N-terminal His tag failed to produce any soluble protein and no 
large band was seen in the lysate pellet. The C-terminal variant showed unchanged 
expression yields. The AChE-d-TRX construct had the TRX tag at the N-terminus. 
Considering even a comparatively small N-terminal hexa His tag prevented the 
expression of active AChE-d, any further addition of residues to the N-terminus of 
AChE-d could reduce the expression of active protein. So it’s possible that a C-
terminal TRX tag would have produced more soluble active protein. 
2.4.3 AChE-d purification.  
The removal of the TRX tag from the AChE-d gene also removed the His tag, this was 
not seen as a problem at the time as an affinity matrix specific for cholinesterases 
was commercially available and it had been used successfully to purify foetal bovine 
AChE from serum (103) and human BChE from serum (104). We can’t know for 
certain whether the batch of procainamide Sepharose that was used in our 
experiments was defective, or if E. coli proteins happen to have a higher affinity for 
procainamide than serum proteins. However the latter seems unlikely as such a large 
proportion of the total E. coli proteins bound to the procainamide Sepharose with a 
similar affinity to AChE-d as illustrated in Figures  8, 9 and 10. It was decided that a 
second batch of procainamide would not be bought due to its high cost of around 
£1000/l. It was for this reason that the His tags were added to AChE-d. After 
optimisation of the Ni affinity and size exclusion chromatography protocols, pure and 
active AChE-d could be recovered at around 2 mg/l of 2YT culture which meant we 
could produce enough for kinetic and homonuclear NMR experiments. 
This purified material was confirmed to be AChE-d as it had the correct molecular 
weight, catalytic activity and was enriched after Ni affinity purification. The cell lysate 
of Shuffle E. coli that had not been transformed with the AChE-d gene gave no signal 
in the Ellmans assay confirming that the signal seen in cell lysate of AChE-d 





Chapter 3. Isotopic labelling of a designed 
isoform of acetylcholinesterase 
3.1 Introduction 
3.1.1 NMR background. 
H, N and C are the most widely studied elements in biological NMR. This is because 
of their abundance in proteins, however, only certain isotopes of these elements can 
be used for high resolution NMR due to their spin ½ nuclei (105). When a spin½ 
isotope is placed in a magnetic field it will either align with the field or against it. It is 
more energetically favourable for the nucleus to align with the magnetic field so in a 
population of spin½ nuclei there will be a small excess of nuclei aligned with the 
magnetic field. The magnitude of this excess increases with the strength of the 
magnetic field. If electromagnetic radiation is applied at the correct frequency it can 
cause the nucleus to rotate out of line to the magnetic field. When the application of 
the electromagnetic radiation stops the nucleus will rotate around the magnetic field 
as it returns to alignment with it. This rotation can induce an alternating electric 
charge in a coil which is shown in NMR spectroscopy as the chemical shift. 
Table 9 shows the spin and natural abundance of a selection of isotopes relevant to 
NMR. 1H is a spin ½ nuclei and has a natural abundance of approximately 99.99% 
making it the most intrinsically sensitive nucleus to observe in protein NMR. 
However, its usefulness is limited by its abundance in proteins and its limited 
chemical shift range. AChE-d produces a spectrum with around 4000 1H signals. 1H 
signals typically occur in a spectral width of around 13 ppm, because of this there 
will be significant peak overlap. This problem is exacerbated for large proteins which 
have slower tumbling rates which gives rise to broader signals (106). This causes 
detailed interpretation of 1D 1H spectra to become very difficult. 15N and 13C are spin 
½ nuclei, but have natural abundances of 0.36% and 1.11% respectively, and their 




rad/T/s) (Table 9). If signals from these isotopes are to be observed in an NMR 
spectrum within a reasonable timescale, isotopic labelling needs to be done. This is 
achieved by growing E. coli in a minimal media with 13C and or 15N compounds being 
the sole source of these elements (107). This results in uniformly labelled protein 
being expressed. If two NMR sensitive nuclei are present in a protein, 2D 
heteronuclear spectra can be collected which greatly reduce the complexity of the 
spectrum. For instance, if a 1H, 15N Heteronuclear Single Quantum Coherence (HSQC) 
spectrum is collected, one peak will be observed for every 1H bound to a 15N (108) 
meaning a 1H, 15N HSQC spectrum of AChE-d would contain around 700 signals. The 
interpretation of a 2D spectrum is also helped by the reduced peak overlap caused 
by the peaks being separated across a plane instead of a single axis. Heteronuclear 
Multiple Quantum Coherence Selective Optimized Flip Angle Short Transient 
(HMQC-SOFAST) experiments function in a very similar way to HSQC experiments but 
they have improved signal to noise at the expense of resolution. Figure 29A and 28B 





Figure 29A. Pulse sequence of a HSQC experiment (109). 28B. Pulse sequence of a HMQC-SOFAST 
experiment (110). 
 HMQC-SOFASTs Improve speed and the signal to noise ratio by using a shaped pulse 
to selectively excite only the amide protons in the protein, the aliphatic and aromatic 
protons remain unperturbed by the shaped pulse. The magnetization is efficiently 
transferred via dipolar coupling to the unperturbed protons, resulting in the amide 
protons having shorter T1 relaxation times. The reduced T1 relaxation time allows a 
faster repetition rate of the experiment allowing more scans to be taken in a unit 
time compared to a standard HSQC. The drawback of HMQC-SOFASTs is that the 
homonuclei (15N in this case) are affected by J-coupling to the protons, this is not 




resulting in reduced resolution (111). There is also no TROSY effect in HMQC-SOFAST 
experiment which also contributes to the broader peaks seen in these experiments 
(112). As the yield of protein was low (0.6 mg/l minimal media culture) HMQC-
SOFAST experiments were used in this work. 
Table 9. Isotope spin, natural abundance and gyromagnetic ratio of the elements that are 
commonly found in proteins or are used to label proteins.    
Isotope Spin Natural abundance 
(%) 
Gyromagnetic 
ratio (107 rad/T/s) 
1H 1/2 99.99 26.75 
2H 1 0.02 4.12 
12C 0 98.90 N/A 
13C 1/2 1.10 6.73 
14N 1 99.6 -7.23 
15N 1/2 0.365 10.14 
19F 1/2 100 25.18 
31P 1/2 100 10.84 
 
 
3.1.2 Uniform 15N vs 13C labelling. 
For this work 15N labelling was chosen over 13C partly due to 15N minimal media 
costing around £13/l (compared to £170 for 13C), and because 1H, 15N HMQC-SOFAST 
give one peak for every residue, excluding prolines, the n terminal residue and each 
of the sidechain amides adds a pair of peaks. 1H, 13C HMQC-SOFAST produce a larger 
number of peaks due to all residues containing multiple C-H bonds. As AChE-d has a 
mass of 62.517 kDa, reducing the complexity of its NMR spectra was a high priority.  
3.1.3 19F labelling. 
19F labelling was also attempted, for this to work E. coli were grown in minimal media 
containing a fluorinated precursor of an amino acid. It is more energy efficient for 




amino acid from raw materials so the 19F precursor gets incorporated into the 
expressed protein (113). For this work fluorinated precursors of tryptophan and 
phenylalanine were investigated. 19F labelling offers the advantage of reduced 
spectral complexity as 19F is not naturally occurring in proteins so only the residues 
labelled will produce signals. AChE-d contains 14 tryptophan and 28 phenylalanine 
residues so labelling either of these would produce a greatly simplified NMR 
spectrum compared to uniform 15N labelling which would produce around 700 peaks. 
19F labelled precursors can negatively affect the expression yield of recombinant 
proteins, this is most likely caused by the larger electronegativity of 19F atom 
compared to the 1H it replaces in the precursor. This can interfere with the correct 
folding of the protein. The effect of precursors containing the 19F in different 
positions on the tryptophan or phenylalanine aromatic ring needs to be tested to 
find the ones that give the highest yield of recombinant protein (114). 
3.1.4 Specific 15N labelling. 
Specific residues can be 15N labelled in a similar way to 19F labelling. E. coli were 
grown in minimal media containing 14NH4Cl and 15N labelled amino acids. The E. coli 
take up the 15N labelled amino acids and use them to make the recombinantly 
expressed protein. All other amino acids are made using the 14NH4Cl so don’t produce 
NMR signals. The opposite, known as un-labelling, can also be done where E. coli are 
grown in minimal media containing 15NH4Cl and specific residues are unlabelled by 
adding amino acids with natural abundance isotopes. This method selectively 
removes certain residues signals from the 1H, 15N HMQC-SOFAST (115). One of the 
downsides of all selective labelling techniques is that E. coli can use certain amino 
acids as precursors for other amino acids in a process known as scrambling. This can 
result in the isotopic label being transferred to amino acids that weren’t intended for 
labelling which increases the background seen in the spectrum. Scrambling can also 
result in 14N being incorporated in amino acids that were intended to be 15N labelled 
which reduces the signal intensity of the peaks (115). Figure 30 gives an overview of 
the intensity that each amino acid will scramble to other residues, it shows that Asp, 
Gln and Glu can’t be selectively labelled with 15N because the amino groups of these 




and His are very amenable to selective 15N labelling as they show no scrambling and 
some residues like Ile, Leu and Val can only be selectively labelled together as 
attempts to selectively label one will cause strong scrambling to the others. 
 
Figure 30. The degree of 15N scrambling in E. coli for each amino acid. A green dot represents no 
noticeable scrambling, an orange dot represents mild but not prohibitive scrambling and a red dot 
indicates that selective labelling will result in the indicated residue being labelled as well as the 
added amino acid. This is an adapted version of Figure 32 from (115). 
3.1.5 Deuteration. 
The HSQC and HMQC-SOFAST spectra of a protein can be improved by growing the 
E. coli and expressing the protein in D2O instead of H2O minimal media. This results 
in the expressed protein having around 70% of its protons replace with deuterons 




amide deuterons to be replaced by protons while all non-exchangeable deuterons 
remain bonded to the protein.  
In a non-deuterated protein, the protons can transfer magnetization to each other 
in a process called spin diffusion (Figure 31 A), this broadens signals because each of 
the magnetisation transfer pathways alter the environment of the protons involved, 
resulting in them having a slightly different chemical shift. Normal oscillations in 
proteins mean that the different relaxation pathways can affect any given proton to 
varying degrees in different protein molecules in the sample. This causes the signal 
from the given proton to be spread out over a wider range of chemical shifts resulting 
in broader peaks. If the concentration of protons in the protein are reduced by 
deuteration (Figure 31 B) then there are less magnetization transfer pathways to 
interact with any given proton so the chemical shift range that each proton signal is 
spread out over is smaller, resulting in sharper peaks. This improves 1H, 15N HMQC-
SOFAST spectra by increasing the signal to noise ratio and resolution. This technique 
is particularly valuable when looking at proteins over 30 kDa as the linewidths 
increase and the signal to noise ratio decreases with increasing protein size. In 
addition to this, 2H has a lower gyromagnetic ration than 1H (Table 9) meaning it 
couples more weakly to other nuclei so will have less of an effect on their chemical 
shifts which also aids the narrowing of linewidths (117). 
 
Figure 31. (A) shows a protonated protein with all of the magnetization transfer pathways between 
protons. (B) Shows a deuterated protein with greatly reduced pathways for magnetization transfer 




3.1.6 Aims of the chapter. 
Each of the labelling methods have different benefits and limitations. Each of them 
was tried and the results were compared to first of all, see if the labelling method 
could be used to produce NMR spectra and secondly, see which one would provide 
the best NMR spectra to identify peak shifts after ligand binding and to infer on 

















3.2 Materials and methods 
3.2.1 Protein expression. 
An altered M9 media was used for expressing labelled AChE-d, the components are 
shown in Table 10. The compounds were dissolved in Milli-Q water.  
Table 10. Composition of altered M9 minimal media used to express isotopically labelled proteins. 
If the expressed protein was intended to be 15N labelled 14NH4Cl was substituted for 15NH4Cl.  







CuCl2 • 2 H2O 2x10-5 
ZnCl2 1x10-4 
MnCl2 • 4 H2O 3.2x10-3 
CoCl2 • 6 H2O 2x10-5 
FeCl3 1x10-3 
H3BO3 2x10-5 
MgSO4 • 7 H2O 0.25 






Test growths were carried out in 250 ml conical flasks containing 50 ml of cell culture. 
Large growths that were intended to produce protein for NMR experiments were 




For specific labelling with either 15N amino acids, or 19F amino acid precursors, main 
cultures containing 14NH4Cl were inoculated at an OD600 of 0.2 from minimal media 
starter cultures and incubated at 37oC with shaking at 180 rpm until OD600 0.4 was 
reached. The temperature was then lowered to 25oC until an OD600 of 0.6 was 
reached. For selective 15N labelling, 100 mg of 15N labelled leucine and isoleucine was 
dissolved in 10 ml of Milli-Q water and filter sterilised then added to the cultures at 
a concentration of 100 mg/l. The culture was left for 15 minutes at 25oC and then 
induced by the addition of IPTG to a final concentration of 0.45 mM. For 19F labelling, 
the 19F precursors were added when the culture reached an OD600 of 0.6. The 
precursors used were 4-fluoroindole, 5-fluoroindole, 6-fluoroindole, 7-fluoroindole 
and 4-fluorophenylacetic acid, all of which were purchased from Sigma-Aldrich. 
These resulted in 4-fluorotryptophan, 5-fluorotryptophan, 6-fluorotryptophan, 7-
fluorotryptophan and 4-fluorophenyalanine being incorporated into the protein 
respectively. Each of the precursors were dissolved in DMSO to a concentration of 
12 mg/ml and kept at 4oC. The chosen precursor was added from the DMSO stock to 
a final concentration of 60 µg/ml in the E. coli culture and left for 15 minutes at 25oC 
before being induced. Cultures were incubated overnight at 25oC with shaking at 180 
rpm.  
For un-labelling, minimal media was made with all the ingredients in Table 10 using 
15NH4Cl and 0.5 g/l of all amino acids apart from leucine, isoleucine, valine, 
tryptophan and cysteine. The media was then filter sterilised by passing it through at 
0.2 µm filter. The media was pre incubated at 25oC and inoculated to an OD600 of 0.5 
from minimal media starter cultures. The inoculated cultures were then incubated 
at 25oC, with shaking at 180 rpm for 30 minutes until the OD600 reached 0.6. 
Expression was then induced by the addition of IPTG to 0.45 mM. The cultures were 
then returned to the incubator and left to express the recombinant protein 
overnight. 
For the deuterated sample, all of the compounds in Table 10 were dissolved in 1 L of 
D2O and filter sterilised. Shuffle E. coli was grown in 3 L of 2YT media at 37 ⁰C to an 
OD600 of 0.5 and the cultures centrifuged at 4000 g for 20 minutes at 4oC. The 




to get them back to their original volume, these cultures were then centrifuged at 
4000 g for 20 minutes at 4oC. The supernatant was discarded, and the pellets were 
washed one more time in the same volume of sterile minimal media. The pellets 
were then re-suspended in 1 L D2O minimal media in a 2.5 L baffled conical flask. The 
flask was placed in a shaking incubator at 25oC with shaking at 180 rpm for 45 
minutes. Protein production was then induced by the addition of IPTG to a 
concentration of 0.45 mM. The flask was then returned to the incubator at 25oC with 
shaking at 180 rpm and left overnight. This method is an altered version of the 
protocol described in (119). 
For all labelling methods, the cell lysis and protein purification procedures were the 
same as previously described in 2.2.3 and 2.2.4.  
3.2.2 NMR experiments. 
All samples were run at 35 oC on a Bruker Avance III 600 MHz (14.1 Tesla) 4-channel 
5-amplifier NMR spectrometer with a QCI-F cryoprobe. All samples were in 20 mM 
phosphate buffer (pH 7.3) containing 100 mM NaCl. 5 % (v/v) D2O was also added to 
all samples. Samples were collected in a 5 mm Shigemi tube with a volume of 320 µl. 
The noise base level used for all HMQC-SOFAST spectra was 28957.7 unless 
otherwise stated. All spectra were referenced on the water peak as 
tetramethylsilane bound not be added to the sample as it bound to AChE-d. 
The 1H 1D experiments used excitation sculpting for water suppression, 32768 
points, 4 dummy and 16 real scans were collected. The spectral width was 16.0242 
ppm. 
1H, 15N HMQC-SOFAST experiments had 1024 points in the F2 (1H) dimension and 
100 points in the F1 (15N) dimension. 4 dummy and 1888 real scans were collected. 
The spectral width was 14.0279 and 36 ppm for F2 and F1 respectively. A gaussian 
window function with a position of 0.2 was applied to all spectra and -25 line 
broadening was used. 
The frequency range that a 19F signal can occur at is larger than the bandwidth than 




collected on the same sample, each of which looked at a different frequency range. 
The 4 spectra were displayed together using Topspins spectra overlay feature. Each 
of the 4 spectra had a spectral width of 40.2570 ppm and were collected for 4 dummy 
scans and 2560 real scans, 8192 points were collected. The O1P was altered in each 
experiment so that spectra 1-4 detected a ppm range of -40 - -80, -80 - -120, -120 - -
160 and -160 - -200 ppm respectively. 


















3.3.1 1H NMR. 
Figure 32 shows a 1H 1D spectrum of AChE-d. There is significant peak overlap caused 
by a combination of the large number and broad linewidths of the peaks. This makes 
1H 1D spectra of large proteins like AChE-d of little use in analysing structural changes 
or dynamics in the protein as changes in individual peaks can’t be observed. 
 
Figure 32. 1H 1D of AChE-d collected for 16 scans and 32K points in the free induction decay (FID) at 
35 ⁰C. The sample was 28 µM in a 5 mm Shigemi tube.  
3.3.2 19F labelling of AChE-d. 
The reduction in expression of active AChE-d caused by recombinant labelling with 
various fluorinated amino acids ranged from 39% caused by 4-fluorophenylalanine 
to 98% caused by 4-fluorotryptophan (Table 11). A drop in the AChE-d activity in the 
lysate supernatant could have indicated either, less AChE-d had been produced or, 
labelled AChE-d had been produced but the resulting protein had a changed specific 




fluorophenylalanine was chosen for further study as it caused the smallest reduction 
in AChE-d activity in the lysate supernatant. AChE-d was expressed in 2 L minimal 
media containing 4-fluorophenyalanine (60 µg/ml). The concentration of the 
resulting 19F-Phe-AChE-d sample was 21.8 µM. The 19F NMR spectrum of this sample 
can be seen in Figure 33, no peaks can be seen in the spectrum even though it was 
acquired overnight.  
5-fluorotryptophan labelling caused the second lowest drop in AChE-d activity (91%). 
Assuming the AChE-d labelled with this precursor had the same specific activity as 
the 4-fluorophenylalanine, a 2 L growth would produce a 3 µM sample which would 
not be usable for NMR experiments. Alternatively, if the yield of AChE-d was higher 
it would have had a greatly reduced specific activity indicating that it wasn’t 
comparable to AChE-d without 19F labelling, therefore any data gained using 4-
fluorotryptophan would not be relevant to wild type enzyme. For this reason, it was 
decided that 19F labelling wouldn’t be suitable for analysing OP inhibition of AChE-d. 
Table 11. AChE-d activities in the lysate supernatant of Shuffle E. coli culture grown with different 
fluorinated amino acid residue precursors. A growth with no fluorinated precursor is included for 
comparison. Protein expression was induced at an OD600 of 0.6 in all cultures. All cultures contained 
0.5 % DMSO as it was required to ensure the solubilisation of the 19F labelled precursors.  
Fluorinated amino acid 
residue 
% of AChE-d activity compared 
to unlabelled growth 
OD600 at 
harvest 
unlabelled 100 1.89 
4-Fluorotryptophan 2.2 1.62 
5-Fluorotryptophan 8.6 1.66 
6-Fluorotryptophan 5.9 1.82 
7-Fluorotryptophan 2.1 1.61 






Figure 33. 19F 1D of 4-fluorophenylalanine labelled AChE-d. Four separate spectra were collected on 
the same 21.8 µM sample. Each spectrum was collected for 2560 scans with 8 K points in the FID at 
35 ⁰C, each of the four spectra covered a different 40 ppm region these were combined to create 
this figure. The peaks seen at -120, -160 and -200 ppm (marked with *) are artefacts of the signal 
filtering and don’t represent real NMR signals. 
 3.3.3 Uniform 15N labelling and deuteration. 
Figures 32 A and B show the same 1H, 15N HMQC-SOFAST spectrum of uniformly 15N 
labelled AChE-d with the noise base level set to two different values. As expected the 
spectrum had very poor resolution due to the large number of peaks and, the broad 
nature of those peaks caused by the large size (62.517 kDa) of AChE-d. The vast 
majority of peaks are so overlapped that attempts to track their movement after 
inhibition with an OP would be impossible. However Figure 34 A shows that the 
spectrum contained a number of peaks around the edge which could be used to track 
ligand binding. Figure 34 B shows several high intensity peaks in the more crowded 
central region. The high intensity of these peaks compared to the others in the 
spectrum indicates they are the peaks of residues in a particularly mobile region of 




were caused by residues on the C-terminal tail they would not likely be affected by 
ligand binding so changes in their chemical shift after inhibition with an OP would 
not be expected. 
Uniform 15N labelling was also attempted in conjunction with 2H labelling, the E. coli 
failed to express suitable amounts of active AChE-d when grown in D2O. Table 12 
shows a comparison of the AChE-d activity in the lysate supernatant of E. coli grown 
in D2O minimal media and the standard H2O minimal media. Even though the E. coli 
grew to a similar OD600 in D2O and H2O minimal media, protein expression in D2O 
resulted in approximately 10 times less active AChE-d being produced. 1 L of minimal 
media produced around 0.6 mg of AChE-d which was enough for roughly 1 NMR 
samples. This meant that to make 1 sample of deuterated AChE-d 10 L of D2O 
minimal media would be needed. The cost of D2O was around £350/l from 
Cambridge Isotope Laboratories meaning £3500 would need to be spent. The D2O 
could be used for 3-4 growths by distilling it after each growth to remove small 
molecule impurities, but the H2O content rises after each distillation meaning the 
deuterium content of the recombinant protein is reduced for every successive 
expression. For these reasons it was decided that producing enough deuterated 








Figure 34. 1H, 15N HMQC-SOFAST of uniformly 15N labelled AChE-d. Collected for 1888 scans with 
1024 points in the 1H dimension and 100 points in the 15N dimension at 35 ⁰C. The sample 
concentration was 24 µM. (A) the noise base level was set to 28957.7. (B) The same spectrum as 




Table 12. Comparison of the AChE-d activity in the lysate supernatant of E. coli grown in H2O and 
D2O minimal media using the protocol in 3.2.1. Both cultures were induced at an OD600 of 1.5. 
Growth media Activity (A412/min/10 µl 
lysate supernatant) 
OD600 at harvest 
D2O minimal media 0.261 3.2 
H2O minimal media 2.427 3.7 
 
3.3.4 Selective 15N labelling. 
Several different methods were used to selectively 15N label AChE-d, first 15N labelled 
isoleucine and leucine were added to minimal media cultures. The AChE-d from this 
growth was purified and analysed by NMR to produce the spectrum shown in Figure 
35. The AChE-d concentration in this sample was 24 µM which would be enough to 
get a HMQC-SOFAST spectrum of a uniformly 15N labelled sample, however, Figure 
35 shows that only four signals were detected. AChE-d contains 12 isoleucines and 
52 leucines, these amino acids also scramble strongly to valine (115) of which there 
are 47 so 111 signals were expected. It was thought that aminotransferase could be 
partially responsible for the weak signals because it catalyses the transfer of amino 
acid amino groups to α-ketoglutarate which is a precursor for several other amino 
acids (115). By doing this aminotransferase essentially dilutes the 15N of the labelled 
leucine and isoleucine into other amino acids. It has been previously shown that the 
addition of α-aminooxyacetic acid (an inhibitor of the aminotransferases) to the 
culture can increase the signals seen by reducing the 15N dilution caused by 
aminotransferase (120). This was attempted but α-aminooxyacetic acid seemed to 
prevent the growth of the E. coli which meant a low yield of active AChE-d was 





Figure 35. 1H 15N HMQC-SOFAST of AChE-d specifically labelled by the addition of 15N leucine and 
isoleucine to the growth media. The sample concentration was 24 µM, the spectrum was collected 
for 1888 scans with 1024 points in the 1H dimension and 100 points in the 15N dimension at 35 ⁰C. 
The noise base level was set to 28957.7 (same as Figure 34 A and 8). 
Un-labelling was studied next, for this experiment Shuffle E. coli were grown in 
minimal media containing 15NH4Cl. All amino acids were added to the media apart 
from leucine, isoleucine, valine, cysteine and tryptophan in their unlabelled form. 
Table 13 shows that roughly double the active AChE-d was produced with this 
method than with a standard minimal media growth. The spectrum of the purified 








Table 13. Comparison of the AChE-d activity in the lysate supernatants of differently labelled E. coli 
cultures. All cultures were grown in standard minimal media with the additions specified in the 
methods section. All cultures were induced at an OD600 of 0.6. 
Labelling method Activity (A412/min/10 µl 
lysate supernatant) 
OD600 at harvest 
None 2.079 1.89 
Un-labelling 4.357 5.4 
Addition of 15N Ile and Leu 2.264 3.8 





Figure 36. 1H 15N HSQC-SOFAST of AChE-d with 15N labelling of leucine, isoleucine, valine, cysteine 
and tryptophan residues. This sample was produced with the un-labelling method described 3.2.1 
and had a concentration of 24 µM. The spectrum was collected for 1888 scans with 1024 points in 
the 1H dimension and 100 points in the 15N dimension at 35 ⁰C. The noise base level was set to 
28957.7 (same as Figure 34 A and 33). The Trp side chain amides are circled in red, the Asn and Gln 





3.4.1 AChE-d expression in minimal media. 
Expressing recombinant proteins in minimal media has been reported to cause a 
drop in yield (121), so the reduced expression yield seen in this work (2 mg/l in 2YT 
media to 0.6 mg/l in minimal media) was expected. 15N labelled yeast extract 
(product name, Celtone Base Powder (15N, 98%+)) can be purchased from Cambridge 
Isotope Laboratories which allows for the uniform 15N labelling of recombinant 
proteins without a drop in protein yield, but these products cost around £70/l of 
culture making it more cost effective to grow larger volumes of minimal media 
instead as there is only a 30% drop in yield and standard minimal media costs around 
£13/l. 
3.4.2 Effects of AChE-d expression in D2O minimal media. 
Deuteration of AChE-d would have greatly improved the signal to noise and 
resolution of spectra obtained (118). Unfortunately, growing E. coli in D2O has been 
shown to reduce overall expression of proteins and increase the doubling time of the 
E. coli, this is mainly caused by the deuterons being more slowly exchanged than 
protons which leads to a slowing of all reactions involving the transfer of protons. To 
overcome this the E. coli need to upregulate the expression of proteins associated 
with these reactions which increases the stress on the cells and decreases the 
resources that are available for other processes (122). It was thought that because 
Shuffle E. coli are under oxidative stress caused by the mutations needed to produce 
the strain (94), that the added stress of deuteration might be to toxic for them. 
However monoclonal antibodies have been successfully deuterated in Shuffle E. coli  
(123), and the Shuffle E. coli grew to similar OD600 in H2O and D2O minimal media (3.7 
and 3.2 respectively) in this work.  This indicates that the difficulty in producing 
deuterated AChE-d is protein specific. Deuteration of non-exchangeable protons has 
been shown to reduce the stability of proteins (124)(114) and it has been shown that 




of deuteration could be the cause of the reduction of soluble and active AChE-d 
expression in D2O but further work is needed to confirm this.  
3.4.3 Effect of 19F labelling on AChE-d expression. 
As Table 13 shows the fluorotryptophans had a much larger effect on the AChE-d 
activity in the lysate supernatant than fluorophenylalanine, and as all cultures grew 
to a similar OD600 it’s unlikely that the difference is due to the fluorotryptophan 
precursors being toxic to the E. coli. The position of the 19F on the indole ring of 
tryptophan has previously been shown to affect the yield of labelled protein, this is 
because fluorine is more electronegative than the proton it replaces which can 
disrupt the correct folding of the protein (126). Therefore several different 19F 
precursors were tested.  
The level of precursor uptake will also influence the AChE-d activity in the lysate 
supernatant, for instance the 4-fluorophenylalanine could have a very large 
detrimental effect on the folding of AChE-d which would lead to a low yield, but if 
the E. coli’s uptake of the precursor is very poor then this effect won’t be seen. AChE-
d contains 14 tryptophans and 28 phenylalanines so fluorine labelling of 
phenylalanine is more likely to interfere with the correct folding of the protein as 
more changes have been introduced. Table 11 shows that E. coli cultures grown with 
the precursor to 4-fluorophenylalanine had the highest AChE-d activity in its lysate 
supernatant so it seems likely that there was a low incorporation of the 4-
fluorophenylalanine precursor into the protein. No examples of specific 19F labelling 
of phenylalanine using 4-fluorophenylacetic acid as a precursor could be found, but 
as phenylacetic acid is a known precursor to phenylalanine (127) it was decided that 
the possibility of using it as a specific label should be investigated.  
Figure 33 shows the 19F 1D NMR spectrum of the 4-fluorophenylalanine labelled 
AChE-d. No peaks can be seen. This could be because there was poor uptake of the 
4-fluorophenylanine precursor or the substantial line broadening of 19F signals 
caused by the combination of the chemical shift anisotropy (CSA) of 19F (128) and 
large size of AChE-d (62.517 kDa). Mass spectrometry has been used to measure the 




getting intact masses of larger proteins comes with significant difficulties (129) which 
prohibited the acquisition of mass spectrometry data on AChE-d without a significant 
investment of time into optimisation. If AChE-d had been selectively labelled with 4-
fluorophenylalanine (which seems unlikely) then Figure 33 showed that the peaks 
produced by the 19F labels were too broad to be detected. If the relatively high 
activity of 4-fluorophenylalanine labelled AChE-d (Table 11) indicated that the 
incorporation of the label had been poor, then successful fluorination of the Phe 
residues would likely result in a substantial drop in AChE-d activity as seen with the 
fluorinated Trp residues, especially considering that AChE-d contains double the 
number of Phe residues compared to Trp. For this reason further investigation of the 
4-fluorophenylacetic acid incorporation efficiency didn’t seem like an efficient use of 
time.  
The correlation time can  affect the amount of peak broadening caused by a nuclei’s 
CSA, increasing correlation time leads to less efficient averaging of the CSA which 
leads to broader peaks (130). 19F has a relatively high CSA, meaning that it will 
produce different chemical shifts depending on the direction it’s measured relative 
to the magnetic field, in solution the tumbling of the molecule containing the 19F 
atom will cause these differences to average out but will result in a broader peak 
than would be caused by isotropic nuclei (131). The combination of this with the peak 
broadening caused by the fast T2 relaxation rate of AChE-d due to its large size was 
expected to cause very broad peaks. Although the acquisition of high resolution 19F 
spectra with good signal to noise ratios was not expected, it was thought that 19F 
labelling experiments should be tried as they were relatively simple and there was 
the possibility that a 19F labelled residue would be in a particularly flexible region of 
the protein and would result in a better than expected signal. The probability of 
gaining usable 19F AChE-d spectra was low, so after the failure of initial attempts to 
produce usable quantities of a 19F labelled AChE-d it was decided that further 
attempts to 19F label AChE-d would not be made. 
3.4.4 Selective 15N labelling of AChE-d. 
Selective 15N labelling of leucine and isoleucine by the addition of 15N labelled amino 




strongly transferred to Val and Ala (Figure 30) leading to isotope dilution. 
Auxotrophic strains of E. coli have been developed that prevent scrambling by 
deleting genes associated with the production of certain amino acids (133). These 
auxotrophs are only commercially available in C43(DE3) E. coli, however, Shuffle E. 
coli is needed to express AChE-d so this method of selective labelling wasn’t pursued 
any further.  
Spectral simplification was the main goal of this work so whilst not ideal, some 
scrambling could be tolerated as it would still result in a spectrum with less peaks 
than uniformly 15N labelled AChE-d. It was for this reason that the selective 15N 
labelling of leucine and isoleucine was attempted. It was expected that leucine and 
isoleucine peaks would have a reduced signal intensity compared to uniformly 15N 
labelled AChE-d and several other residue types would also produce relatively weak 
signals. Unfortunately, the scrambling was so severe that the 15N concentration of 
each affected residue was too low to be detected. It was shown in (120) that the 
addition of the aminotransferase inhibitor α-aminooxyacetic acid could prevent the 
scrambling of the 15N isotope on leucine so its addition to the growth media was 
tested but resulted in the growth of E. coli being halted and a negligible amount of 
AChE-d activity being detected in the lysate supernatant (Table 13). In reference 
(120), the E. coli strain BL21 (DE3) were used with good results, however, Shuffle E. 
coli are already under considerable oxidative stress and hence may cope less well 
with the additional stress of aminotransferase inhibition, resulting in the cessation 
of cell growth and no recombinant protein production.  
The intention of the un-labelling experiment was to simplify the HMQC-SOFAST of 
AChE-d by removing the peaks from all residues except leucine, isoleucine, valine, 
tryptophan and cysteine. These residues were chosen for a variety of reasons. 
Leucine, isoleucine and valine make up 20% of residues in AChE-d so having just these 
15N labelled would produce a HMQC-SOFAST spectrum with 111 peaks, it was 
thought that this would sufficiently simplify the spectrum whilst still providing 
enough peaks to track movement on inhibition of the enzyme with an OP. 
Tryptophan was included because of its abundance in the active site gorge of AChE-




the catalytic triad at the base of the gorge (24). The tryptophan sidechain amides 
occupy a sparsely populated region of the spectrum from a 1H, 15N HMQC-SOFAST 
experiment and are seen in the bottom left hand corner of Figures 34 circled in red. 
This is an added bonus as it provides extra peaks to analyse whilst not increasing the 
complexity of the main body of the spectrum. Cysteine could not be included in the 
growth media as it inhibits the production of leucine, isoleucine, valine and threonine 
which stops the E. coli from growing (134). AChE-d only contains 6 cysteines so their 
inclusion into the HMQC-SOFAST spectra wasn’t a major concern.  
The un-labelling doesn’t seem to have worked as expected, in Figure 36 the sidechain 
amide peaks of Asp and Gln can be seen as the two clusters of peaks in the top right 
corner of the spectrum circled in green. These amino acids were added in the same 
concentrations as all the others. It has been shown that the sidechains of Asp and 
Gln can be selectively 15N labelled by expressing proteins in minimal media 
containing all amino acids (including Asp and Gln) with 15NH4Cl (135). For this reason, 
it’s unlikely that their removal from the spectrum would be simple.  
3.4.5 Conclusions.  
Figures 32, and 34 have the noise base level set to the same value, meaning that only 
peaks above an intensity level of 28957.7 are shown in all spectra. When comparing 
the spectra it’s apparent that Figure 36 (15N sample all residues un-labelled apart 
from Ile, leu, Val, Cys and Trp) has a greatly simplified spectrum compared to Figure 
34 A (uniformly 15N labelled). However, many of the peaks on the periphery of Figure 
34 A are lost in Figure 36. Any change in these peaks position after inhibition of AChE-
d by an OP would be relatively easy to observe as the reduced spectral density 
around the perimeter of the spectrum reduces peak overlap. The loss of these peaks 
in Figure 36 is a disadvantage of the un-labelling method. However, several peaks in 
the central region of Figure 36 become better resolved due to un-labelling. Figure 34 
B is taken from the same spectrum as Figure 34 A but the noise base level is set higher 
to remove more of the spectrum. Compared to Figure 36 there are less peaks 
because the less intense peaks were below the higher noise base level but several 
peaks remain which show limited overlap so could still be used to track peak shifts. 




remove even more viable peaks on the periphery of the spectrum. For this reason, 
uniform 15N labelling was chosen as the labelling method to use for studying OP 

























Chapter 4. Kinetic analysis of organophosphate 
inhibition and oxime reactivation. 
4.1 Introduction. 
4.1.1 Organophosphate (OP) inhibition of AChE-d.  
A schematic overview of the inhibition of AChE-d by an OP is shown in Figure 37, the 
first step is the reversible binding of the OP to AChE-d (Figure 37 A). Once bound the 
oxygen of the active site serine can form a covalent bond with the phosphorus atom 
of the OP which causes the bond between the phosphorus and the leaving group to 
break. This leaves the phosphate adduct covalently bound to the active site serine 
(Figure 37 B) which prevents AChE-d from catalysing the hydrolysis of ATCh (58). 
Oximes, which have an R=NOH functional group (R being any other chemical group) 
can be used to remove the phosphate adduct from OP inhibited AChE-d. The O of 
the oxime group forms a covalent bond with the phosphorus atom of the adduct by 
a nucleophilic attack reaction, this causes the bond between the phosphorus atom 
and the O of the active site serine to break releasing reactivated AChE-d and a 
phosphorylated oxime (141) (Figure 37 C).  
The phosphate adduct can also undergo spontaneous hydrolysis, this is where a 
covalent bond is formed between the phosphate and the O of a water molecule, 
causing the release of a H+ from the water and the phosphate adduct from AChE 
(142) (Figure 37 D). The R2 group is susceptible to hydrolysis as well, this produces a 
negatively charged phosphate adduct that can’t be reactivated with oximes and 
doesn’t undergo spontaneous hydrolysis as the negative charge on the adduct 
protects it from nucleophilic attack (143) (Figure 37 E). The susceptibility of each OP 
to the post inhibition reaction pathways is different, for example the chemical 
warfare agent soman has an extremely fast ageing half-life of around 4 minutes 
(144), most other OPs have ageing half lives in the range of hours (145)(146). Tabun 
which is another chemical warfare agent OP is roughly 10 times more resistant to 




(65) which are also organophosphorus chemical warfare agents. The half-lives of 
spontaneous hydrolysis of OP inhibited AChE ranges from 1 – 40 hours (146)(147) 
which means spontaneous hydrolysis has little relevance to the toxicity of an OP as 
after acute poisoning with an OP death would occur before any significant 
spontaneous hydrolysis. 
 
Figure 37. Schematic diagram of the inhibition of AChE by an OP and the subsequent reactions of 
the OP inhibited AChE. E represents the enzyme R1 and R2 represent any other chemical group and 
X represents the leaving group of the OP. This Figure is an altered version of one taken from (58).  
 
Figure 38. Structures of the two oximes used in this work. 
4.1.2 Experimental aims.  
The main aims of this chapter were to measure kinetic data for the inhibition of 
AChE-d by several OPs (Figure 39) and the subsequent oxime mediated reactivation 
of the OP-AChE-d conjugates using the oximes in Figure 38. This data was intended 
to be compared with NMR data on the interaction of OPs with AChE-d to see if OPs 
with different kinetic parameters perturbed different residues in AChE-d. This could 
suggest that the adducts were causing structural changes in AChE-d which could help 
explain the differences in the OPs rates of reactivation or determine if association of 
the adduct with certain residues had a protective effect against reactivation. 




groups on OPs that were in particularly close proximity to AChE-d, this information 
could be used to infer which chemical groups were important for binding. The 
inhibition rates were collected to see if they correlated with the LD50s of the OPs, 
which would mean they had predictive value in assessing the OP toxicity. 
The inhibition and reactivation kinetics could only be determined for pesticide OPs 
as the collaborating laboratory at Defence Science and Technology Laboratory were 
unable to support the analysis to obtain kinetic data on the chemical warfare agents 
covered by this study. The inhibition and reactivation rates for chemical warfare 
agent and pesticide OPs with human AChE had been published (65). Therefore an 
additional aim of this work was to compare the reactivation rates of the pesticide 
inhibited human AChE in reference (65) with experimentally determined values using 
AChE-d. If the ranking of relative reactivation rates for the pesticide OPs was the 
same for human AChE and AChE-d then it would be likely that the organophosphorus 
chemical warfare agents would follow the same trend in both isoforms.  
 










4.2.1 Determination of AChE-d stability. 
The effect of BSA concentration on the degradation rate of AChE-d was tested. For 
this experiment five different 100 µl samples of 100 nM AChE-d were made with 
varying BSA concentrations. The BSA concentrations were, 0, 0.1, 0.2, 0.3 and 0.4 
mg/ml. These were left at room temperature for one hour, every 10 minutes 10 µl 
of each sample was taken and used to determine the rate of AChE-d mediated 
breakdown of ATCh according to 2.2.5. 
4.2.2 Determination of OP inhibition rates and affinities for AChE-d. 
Stock solutions of 50 mM OP were made up in methanol just before use and kept on 
ice, these were then used to make stock solutions 10 X the concentration that was 
needed in the assay (Table 14). A stock solution of 1 µM AChE-d and 1mg/ml BSA was 
made in phosphate buffer (20 mM sodium phosphate, 100 mM NaCl, pH 7.4) and 
kept on ice. Samples for measuring the rate of inhibition were made by adding 10 µl 
of the AChE-d/BSA stock solution to 80 µl of phosphate buffer, 10 µl of the 
appropriate 10 X OP stock solutions was then added. Periodically 10 µl of the sample 
was taken for rate determination according to 2.2.5. This was done after 1, 2 and 3 
minutes for methamidophos and 2, 4 and 6 minutes for fenamiphos. A rate 
determination assay can be done every 1 min. (21 s for the experiment to run and 
the rest of the time is used pipetting and changing cuvettes), azamethiphos and 
chlorfenvinphos inhibited AChE-d rapidly meaning in their inhibition assays samples 
needed to be taken after 10, 20 and 30 and 20, 40 and 60 seconds of incubation 
respectively, because the activity can only be taken once every minute one sample 
could not be used for all measurements, so separate samples were made for each 







Table 14. The concentration of each OP used in assays to determine the inhibition potencies and 









0.05 2 0.1 0.1 
0.1 4 0.25 0.2 
0.15 6 0.5 0.3 
0.2 8 0.75 0.4 
0.3 10 1 0.5 
0.4 12 1.5 0.75 
 14 3  
 
The rate of inhibition was measured and the natural logarithm derived, these were 
then plotted against incubation time and fitted to a straight-line using Excel, and this 
was repeated for each OP concentration. The slope of the straight line gave the 
pseudo first order rate constant (k’) (148) for the reaction of the OP with AChE-d. In 
reference (149) the oxime induced reactivation of OP inhibited human AChE was 
shown to follow Michalis-Menten kinetics which lead them to derive the altered 
Michalis-Menten equation given in Equation 2. The reaction scheme for OP inhibition 
is identical to the oxime induced reactivation (Figure 40 A and B) meaning the 
Michalis-Menten equation can be used to approximate the kinetics for OP inhibition. 
The Michalis-Menten equation was fit to plots of k’ against OP concentration using 
the non-linear regression tool in the KaleidaGraph software package. This allowed 
values for kr and Kd to be determined. 
𝑘𝑜𝑏𝑠 =
𝑘𝑟 ∗ [𝑜𝑥𝑖𝑚𝑒] 
𝐾𝑑 + [𝑜𝑥𝑖𝑚𝑒]
 
Equation 2. Micaelis-Menten equation with parameters named according to reference (65). Kobs is 
the observed rate of reaction, kr is the maximal rate of reaction and Kd is the dissociation constant. 






Figure 40. Reaction scheme for OP inhibition of AChE-d (A) and oxime mediated reactivation of OP 
inhibited AChE-d (B). E represents AChE-d, OPx the organophosphate with the leaving group (x) 
attached, EOPx the reversible complex between the OP and enzyme, EOP the phosphorylated 
enzyme and x the leaving group of the OP. OX represents the oxime, EOPOX the reversible complex 
between the phosphorylated enzyme and the oxime. OPOX represents the phosphorylated oxime. 
Kd is the concentration of either OP or oxime that give 50% maximum rate of reaction and kr is the 
rate of reaction when the concentration of OP or oxime approach ∞. 
4.2.3 Determination of OP stability. 
Samples of each of the four OPs in Figure 39 were made at a concentration of 0.5 
mM in phosphate buffer (20 mM sodium phosphate, 100 mM NaCl, pH 7.4) 
containing 5% deuterated methanol, the final sample volume was 600 µl and all 
samples were in 5 mm NMR tubes. The IconNMR mode of the TOPSPIN software 
package was used to automate the periodic collection of 1H 1D spectra for each of 
these samples. It took 40 minutes to collect a spectrum on all the samples (10 min 
per sample), after this the process was repeated so a spectrum of each sample was 
collected every 40 minutes, this process was continued for 20 hours.  
The 1H 1D NMR experiments used excitation sculpting for water suppression, 32768 
points, 4 dummy and 4 real scans were collected. The spectral width was 16.0242 
ppm and the temperature was 25⁰C. 
The decrease in signal intensity of the OPs relative to the methanol signal was used 
to assess the breakdown of the OPs.  
4.2.4 Reactivation of OP inhibited AChE-d. 
To produce OP inhibited AChE-d, a 400 µl sample containing 5 µM AChE-d, 1 mM OP 
and 5% methanol was made in phosphate buffer (20 mM sodium phosphate, 100 
mM NaCl, pH 7.4) and then, incubated at room temperature for 30 minutes after 




sure over 95% of the AChE-d activity had been lost. Unreacted OP was removed from 
the sample by passing in through a 2 ml PD-10 desalt column (GE healthcare) which 
had been washed and pre equilibrated with phosphate buffer according to 
manufacturer’s instructions. After the OP inhibited AChE-d sample had passed 
through the column its protein concentration was assessed by A280 measurement, it 
was then diluted in phosphate buffer to 1 µM and BSA was added to a concentration 
of 1 mg/ml, this stock solution was kept on ice. Appropriately concentrated stock 
solutions of oximes were made in phosphate buffer and kept on ice. Around 4 to 5 
test samples were made containing 100 nM OP-AChE-d conjugate, 0.1 mg/ml BSA 
and varying concentration of oxime and periodically checked for AChE-d activity, this 
was done do determine the range of oxime concentrations necessary to achieve a 
saturation curve and the incubation time that would allow a detectable amount of 
AChE-d to be reactivated but not so much that all samples showed complete 
reactivation of AChE-d.  
The oxime concentrations used to get saturation curves for oxime reactivation 
experiments were 0 - 1400 µM in 100 µM increments for all experiments apart from 
the obidoxime reactivation of chlorfenvinphos inhibited AChE-d. In that experiment 
the obidoxime concentrations were 0 - 3.9 mM in 0.3 mM increments. The rate of 
ATCh breakdown by AChE-d was measured at each oxime concentration after the 
pre-determined incubation time. These rates were then converted into the observed 
rate constant (kobs) using Equation 3. The kobs values were plotted against oxime 
concentration and the non-linear regression tool in the KaleidaGraph software 







Equation 3. Used to convert the rate of reaction into the pseudo first order observed rate content 
(kobs). V0 is the rate of uninhibited AChE-d, Vt is the rate of an OP-AChE-d conjugate at time t in the 
incubation with an oxime and Vi is the rate of OP-AChE-d conjugate before incubation with an 






4.2.5 Measurement of oxime IC50s. 
Stock solutions of each oxime were made in phosphate buffer (20 mM sodium 
phosphate, 100 mM NaCl, pH 7.4), the oxime concentrations of these stock solutions 
(in mM) were, 1000, 750, 500, 300, 200, 100, 50, 10, 5 and 1. A stock solution 
containing 100 nM AChE-d and 0.1 mg/ml BSA was made, this was kept on ice until 
needed along with the oxime stock solutions. Cuvettes containing 980 µl Ellmans 
buffer, 10 µl of the appropriate oxime stock and 10 µl of the AChE-d BSA stock were 
made. The AChE-d activity of these samples was obtained using the methods in 2.2.5. 
Three rate measurements were obtained for each oxime concentration. The oximes 
reacted with ATCh so the rate of oxime mediated breakdown of ATCh at each oxime 
concentration was measured by adding 10 µl of the appropriate oxime stock solution 
and 10 µl phosphate buffer to 980 µl of Ellmans buffer then measuring the rate of 
reaction using the same method as the samples containing AChE-d. The rate of oxime 
mediated breakdown of ATCh was subtracted from the rate of reaction obtained 
from the sample containing AChE-d and the corresponding concentration of oxime. 
The data was fitted to logarithmic equations using Excel which allowed the oxime 














4.3 Results  
4.3.1 Stabilisation of AChE-d.  
Dilute samples of AChE have been shown to be unstable at room temperature, this 
instability could be overcome by increasing the concentration of AChE in the sample 
(151). It was investigated weather BSA could also be used to prevent the breakdown 
of AChE-d, the results of this are given in Figure 41. The AChE-d sample containing 
no BSA lost roughly half of its activity over the hour long period it was observed and 
all samples containing BSA showed no significant drop in activity. All kinetic 
experiments from this point on included 0.1 mg/ml of BSA to prevent degradation of 
AChE-d, the lowest tested BSA concentration was chosen to minimise the chance of 
it affecting the kinetic assays by binding to the substrates, inhibitors or oximes.  
 
Figure 41. Activity of 100 nM samples of AChE-d containing varying concentrations of BSA over 1 
hour at room temperature. n=1. 
4.3.2 Organophosphate inhibition of AChE-d. 
The maximum inhibition rate (kr) and Kd of the four OP insecticides shown in Figure 





































first order rate constant (k’) for the inhibition of AChE-d by each of the OPs are shown 
in Figure 42, these were used to calculate the kr and Kd for each inhibitor. The errors 
on the measurements of azamethiphos (Figure 42 A) were relatively large compared 
to the other OPs, this was because azamethiphos inhibited AChE-d at a very fast rate 
meaning only small amounts of the detectable product of the Ellmans assay could be 
generated resulting in the inherent noise of the assay being a more significant 
portion of the measured value.  
 
Figure 42. The pseudo first order rate constants of inhibition (k’) plotted against OP concentration 
for azemethiaphos (A), fenamiphos (B), methamidophos (C) and Chlorfenvinphos (D). Each data 
point was the mean of three measurements and the error bars represent the standard deviation. 
kr and Kd values couldn’t be determined for chlorfenvinphos because it started to 
precipitate at 400 µM meaning the plateau seen in Figure 42 D is due to the reaction 
buffer being saturated with chlorfenvinphos. However, from Figure 42 it can be 
determined that at an OP concentration of 100 µM chlorfenvinphos had the second 




saturation point of methamidaphos and fenamiphos indicating it had a kr larger than 
both of these OPs.  
 
Table 15. The kr and Kd values for each of the OP used to inhibit AChE-d. Chlorfenvinphos 
precipitated out of solution at 400 µM which was not high enough for it to saturate AChE-d so kr 
and Kd could not be calculated. The errors were calculated by the KaleidaGraph software package. 
The LD50 values were measured on rats with the OP being administered orally and were taken from 
the references indicated next to the LD50 value.  
OP kr (s) Kd (µM) LD50 (mg/kg) 
Azamethiphos 0.186 ± 0.012 123.27 ± 21.69 1180 (152) 
Fenamiphos 0.008 ± 0.001 726.02 ± 141.43 8.1 (153) 
Methamidophos 0.031 ± 0.003 6792.5 ± 1369.8 30 (154) 
Chlorfenvinphos N/A N/A 23 (155) 
 
4.3.3 Measurement of OP stability.  
It was thought that the degradation rate of the OPs could be affecting their inhibition 
rates, to test this, 0.5 mM samples of each of the OPs were made in phosphate buffer 
(20 mM sodium phosphate, 100 mM NaCl, pH 7.4) containing 5% deuterated 
methanol. 1H 1D NMR spectra were collected of each of these samples every 40 
minutes for 20 hours and the reduction in peak intensity was used to assess the 
breakdown of the OPs. Methamidophos was the only OP that showed noticeable 





Figure 43. The reduction in signal intensity of each OP over a 20 hour period.   
4.3.4 Oxime mediated reactivation of OP inhibited AChE-d. 
The two oximes shown in Figure 38 were tested for their ability to reactivate AChE-
d which had been inhibited by the OPs shown in Figure 39. Samples of OP inhibited 
AChE-d (100 nM) were incubated with varying concentrations of the chosen oxime 
for a predetermined period of time. Following incubation with oxime, 10 µl of the 
sample was added to 990 µl Ellmans buffer and the AChE-d activity measured. The 
AChE-d activity was then plotted against oxime concentration to produce the graphs 
shown in Figure 44. 
The non-linear regression function of the KaleidaGraph software package was used 
to fit Equation 2 to the graphs in Figure 44. This allowed values for kr and Kd to be 
determined. kr gave the rate of reactivation at a saturating concentration of oxime 
and Kd gave the concentration of oxime that produced 50% of the maximum 
reactivation rate so represented the affinity of the oxime for the OP inhibited AChE-
d. The values of kr and Kd for each of the OP oxime pairs are given in Table 16 and 
shown graphically in Figure 45. Obidoxime showed a faster rate of reactivation than 




































both oximes (0.771 min for pralidoxime and 0.995 min for obidoxime), the kr values 
for the other OPs ranged between 0.001 – 0.034 min for pralidoxime and 0.005 – 
0.052 min for obidoxime. The Kd values showed that obidoxime was a weaker binder 
for all OP-AChE-d conjugates apart from methamidaphos (Figure 45 B) and that 
obidoxime had a surprisingly low affinity for chlorfenvinfos inhibited AChE-d, the Kd 
was roughly four times higher than that of the other OP-AChE-d conjugates. 
 
Figure 44. Reactivation rates (kobs) of pralidoxime (blue) and obidoxime (red) for AChE-d inhibited 
by each of the four OP pesticides. Graphs (A), (B), (c) and (D) are for AChE-d inhibited by 
azamethiphos, fenamiphos, methamidaphos and chlorfenvinphos respectively. All data is the mean 








Table 16. The reactivation rates (kr) and dissociation constants (Kd) for two oximes and AChE-d 
inhibited with different OP insecticides. Data is a mean of two repeats, the standard deviation is 
given as the errors.  
 Pralidoxime Obidoxime 
OP used to 
inhibit AChE-d 
kr (min) Kd (µM) kr (min) Kd (µM) 
Azamethiphos 0.034 ± 0.001 271.37 ± 41.28 0.049 ± 0.003 512.80 ± 86.46 
Fenamiphos 0.001 ± 0.000 298.61 ± 42.29 0.005 ± 0.000 471.07 ± 72.05 
Methamidaphos 0.771 ± 0.030 714.00 ± 60.58 0.996 ± 0.072 619.29 ± 104.35 
Chlorfenvinphos 0.007 ± 0.000 232.68 ± 31.43 0.025 ± 0.001 1938.90 ± 
222.00 
 
The size of the phosphate aduct that inhibits AChE-d was thought to have an effect 
on the reactivatability of the OP-AChE-d conjugate, for this reason the size of the 
phosphate aduct was estimated for each of the four OPs. The atomic radi were taken 
from reference (156) and Equation 4 was used to calculate the atomic volume (Table 
17). The size of the phosphate aducts were estimated by adding together the 
volumes of all the nuclei they contained (Table 18). The estimated molecular 
volumes are likely to be considerable overestimates because all atoms are asumed 
to have no overlaping sections, in reality the chemical bonds between atoms will 
cause significant overlap between atoms. However, for the purpose of comparing 
the size of the phosphate aducts to their reactivation rates the total volume of the 
aduct isn’t particularly important as the errors will be consistent for all aducts 
meaning the molecular volume estimates will be comparable to each other. 
Interestingly the larger phosphate aducts had slower reactivation rates. As Figure 46 
A shows  the relationship was aproximatly linear for azamethiphos, chlorfenvinphos 
and fenamiphos but the reactivation rate of methamidophos was too fast to fit the 
trend of the other three OPs. The Kds of the oximes for the OP-AChE-d conjugates 






Figure 45. Graphical representation of the kr (A) and Kd (B) values for the reactivation of OP inhibited 












Table 17. The atomic radi of several different elements found in OPs. The values of atomic radii 
were taken from reference (156), the volumes were calculated using Equation 4. 
Element Radius (pm) Volume (nm3) 
H 25 65 
C 70 1400 
N 65 1200 
O 60 900 
P 100 4200 
 
Table 18. Estimate of the size of the phosphate adduct left bound to AChE-d after inhibition with 
each OP. 




Fenamiphos O2PH13NC5 15045 
Chlorfenvinphos O3PH10C4 13150 
Azamethiphos O3PH6C2 12890 






Figure 46. (A) The oxime mediated reactivation rates of AChE-d inhibited by four different OPs 
plotted against an estimate of the molecular volume of the phosphate groups left by the OPs after 
inhibition. (B) The Kds of the oximes for each of the OP-AChE-d conjugates plotted against the 
estimated volume of phosphate adducts. 
4.3.5 Oxime inhibition of AChE-d. 
The AChE-d activity was measured in the presence of different concentrations of 
each of the oximes in Figure 38, this was done to obtain IC50 values for the oximes as 




very similar (pralidoxime 630.39 ± 131.94 and obidoxime 691.00 ± 49.51) and the 
errors of the measurements overlapped meaning there wasn’t a significant 
difference in their inhibitory potencies.  
 
Figure 47. The percentage of total AChE-d activity in the presence of different concentrations of 
obidoxime and pralidoxime. The error bars represent the standard deviation of three 
measurements. The logarithmic equations fitted to each data set are shown in the corresponding 
colours.  
 
Table 19. The IC50 values of obidoxime and pralidoxime for AChE-d. Values are the mean of three 
experiments and the errors are the standard deviation.  
Oxime IC50 (µM) 
Pralidoxime 630.39 ± 131.94 
Obidoxime 691.00 ± 49.51 
 
y = -13.26ln(x) + 135.01
R² = 0.975





































4.4.1 Organophosphate inhibition rate and affinity as an indicator of toxicity. 
Table 15 contains the kr, Kd and LD50 values for each of the OPs in Figure 39. 
Azamethiphos was the least toxic (LD50 of 1180 mg/kg) but had the highest kr (0.186 
± 0.012 s) meaning it was the most inhibitory OP. Fenamiphos which was the most 
toxic (LD50 8.1 mg/kg) but had a kr 23 times smaller than azamethiphos, this indicated 
that kr was a poor indicator of the toxicity of an OP as a high kr didn’t indicate that 
an OP would be toxic. The Kd also proved to be a poor indicator of toxicity, 
azamethiphos had the lowest value (123.27 ± 21.69 µM) indicating it had the highest 
affinity for AChE-d, fenamiphos and methamidophos had Kds 6 and 55 times higher 
respectively but their LD50s were 146 and 39 times lower. The discrepancy between 
the efficacy of the OPs as AChE-d inhibiters and their toxicity could be caused by the 
fact that the LD50s were obtained using rats, and as discussed in section 1.3.3, AChE-
d and rat AChE have 83% sequence similarity. The differing 17% could cause the two 
AChE isoforms to have different susceptibilities to OP inhibition meaning that if the 
in-vitro kinetic experiments were repeated with rat AChE the inhibitory kinetics 
would show a closer correlation with the LD50 values. In section 1.2.1 it was 
demonstrated that the most toxic insecticide of a selection of OPs and carbamates 
varied between two different species of insects. In vitro experiments have also 
shown diisopropyl fluorophosphates (DFP) to inhibit human AChE 4 times faster than 
it does rat AChE. The same study also showed that nitrophenyl cyclohexyl 
methylphosphonate inhibited rat AChE 2 times faster than human (157). The species 
differences could explain the discrepancy between inhibition kinetics and LD50 but 
these experiments would need to be repeated with rat AChE to investigate this 
further. 
A second possible explanation for the poor correlation between OP inhibition and 
toxicity is biological detoxification of the OP. An OP with a high inhibition rate will 
have a low toxicity if it is rapidly broken down in vitro. House flies were reported to 
have developed resistance to azamethiphos by upregulating OP degrading enzymes 




breakdown of OPs clearly has a significant effect on the toxicity of OPs and it is not 
unreasonable to hypothesize that different OPs could have different susceptibilities 
to the enzymes involved in their detoxification. It would be interesting to get in vitro 
data on the breakdown rates of different OPs by the main detoxifying enzymes (GST, 
cytochrome P450, paraoxonase and phosphotriesterase) and see if these values help 
to predict the toxicity of OPs.  
In an attempt to make the data collected in this project comparable with previously 
published data on the inhibition and reactivation rates of chemical warfare agent 
OPs all data was analysed using the methods published in references (150) and (65). 
4.4.2 OP degradation rate. 
The only OP which degraded by a noticeable amount over the 20 hour time period 
measured was methamidophos. It took 2 hours for the sample to degrade by roughly 
3% and as stocks of this OP weren’t kept for longer than 2 hours the degradation of 
methamidaphos would have had a negligible effect on the results of the inhibition 
assay.  
It was thought that the stability of the OPs could also have an effect on their LD50s. 
Depending on the OP and the dose ingested, the symptoms of poisoning can 
manifest after several minutes to several hours (159) and as Figure 43 showed all 
OPs except methamidophos were stable for 20 hours. Even though methamidophos 
was the least stable it had only degraded by 30% after the 20 hour incubation at 
room temperature and physiological pH which would leave a large window of time 
for it to inhibit AChE in an organism before non-biological breakdown caused a 
significant reduction in its physiological concentration.  
4.4.3 OP susceptibility to oxime reactivation. 
It was interesting that for all tested OPs obidoxime had a faster reactivation rate than 
pralidoxime but showed a reduced affinity (apart from with methamidophos 
inhibited AChE-d). This indicated that obidoxime must have been more reactive 
towards the phosphate adduct of OP inhibited AChE-d than pralidoxime. A previous 




by the same OP adducts as the ones used in this study (65), however, obidoxime was 
shown to bind tighter than pralidoxime to all OP- human AChE conjugates apart from 
methamidophos. Interestingly the opposite result was obtained using AChE-d. The 
reactivation experiments in reference (65) were carried out at 37oC, this would have 
contributed to the differences seen in the values obtained for kr and Kd but the 
change in values should have been consistent for each OP-AChE-d conjugate, this 
was not the case. Reference (65) used human red blood cell ghosts as the source of 
AChE which had a 10% difference in sequence identity compared to AChE-d. These 
differences caused a change in the catalytic rate of AChE-d (80) so it is possible that 
they would also change the affinity of the enzyme for the two oximes. The use of red 
blood cell ghosts also meant that membranes were present in all stages of the 
protocol, and to overcome the degradation of AChE at low protein concentrations 
the red blood cell ghosts were re-suspended in human plasma that had been treated 
with soman to remove BChE activity and then dialysed to remove excess soman. The 
lipids and plasma proteins present in the OP inhibited human AChE sample could 
have interacted with the oximes which is another possible contribution to the 
differences seen in the reactivation rates. These differences meant that NMR data 
collected on organophosphorus chemical warfare agents interactions with AChE-d 
could not be compared to the kinetic data in reference (65) because the differences 
in the two AChE isoforms would likely cause AChE-d to have an altered ranking of kr 
and Kd values for the OP chemical warfare agents than human AChE. This would 
mean that any changes a chemical warfare agent OP caused in the NMR spectrum of 
AChE-d could not be related to reactivation rate as this data was not available.  
The data for the reactivation of chlorfenvinphos inhibited AChE-d by obidoxime 
(Figure 44 D) is interesting as it gave a Kd of around 1.9 mM, the other OPs had Kds in 
the range of 250 – 750 µM. A new sample of chlorfenvinphos inhibited AChE-d was 
made and its reactivation by obidoxime was retested using the same methods as 
before, the Kd obtained in this repeat was around 1.5 mM. Although the repeat 
produced a smaller Kd it was still larger than would be expected based on the Kds of 
other OPs. With the exception of chlorfenvinphos, all the Kds for pralidoxime and 




showed a difference of over a mM in the Kds for the two oximes. At the 
concentrations used in this assay the obidoxime induced hydrolysis of ATCh was 
insignificant so after accounting for it the Kd values were unchanged. Spontaneous 
hydrolyses of the phosphate adduct was unlikely to be the cause as the Kd of 
pralidoxime for chlorfenvinphos inhibited AChE-d would also have been high, in 
reality it was 233 µM.  
Figure 46 A showed that the size of the phosphate adduct that was left covalently 
bound to the active site of AChE-d after inhibition by an OP was a relatively good 
indicator of how susceptible it would be to reactivation. Unsurprisingly the size of 
the adduct didn’t appear to be the only factor effecting reactivation as the 
relationship between size and reactivation rate was not linear for all OPs but the 
trend did show that smaller adducts were reactivated faster. This trend was not seen 
when plotting Kd against phosphate adduct size which meant based on this data the 
size of the adduct had no predictive value on the affinity of oximes for OP inhibited 
AChE-d. 
Only four OPs and two oximes were used in this work which was a small data set, this 
meant that more OPs and oximes needed to be tested to confirm these results. It 
would also be interesting to test OP oxime pairs with a wider range of reactivation 
rates, Kds and molecular volumes than those presented in this data set. This would 
allow the relationship between reactivation kinetics and adduct size to be more 
accurately determined and help to identify if any relationships does exist between 
Kd/kr and adduct size.   
4.4.4 Inhibition potency of the oximes.  
Based on pralidoxime having a lower Kd than obidoxime for all OP-AChE-d conjugates 
apart from methamidophos, it was assumed that pralidoxime would have a lower 
IC50 for AChE-d than obidoxime. However, as Figure 47 and Table 19 show, the 
difference between the IC50 values for the oximes ware not statistically significant.  
For an oxime to reactivate OP inhibited AChE-d it would likely need a certain affinity 
for AChE-d but, as this work showed, two oximes with the same affinity for AChE-d 




d is unlikely to be a good indicator of usefulness of an oxime as a countermeasure to 

















Chapter 5. NMR investigation of the inhibition of 
a designed isoform of acetylcholinesterase by 
organophosphates. 
5.1 Introduction. 
5.1.1 Background to Saturation Transfer Difference (STD) NMR. 
STD NMR was developed by Moriz Mayer and Bernd Meyer in 1999 (160), the 
technique was developed to allow the detection of small molecules binding to larger 
proteins using the small molecule signal as the reporter. The experiments utilised 
shaped pulses to specifically excite small (around 1 ppm) regions of the spectra (161). 
These shaped pulses saturate the resonances that they hit, meaning that the energy 
difference between the high and low energy spin states is equalised (162) and 
because NMR relies on this small difference in the energy levels of spin states to 
detect a signal (163), saturation results in the signal becoming undetectable. 
The premise of the experiment was that two 1D spectra would be collected of a 
protein ligand sample, one spectrum would have the shaped pulse set far away from 
any protein or ligand resonances (around -30 ppm), this would result in a standard 
1D spectrum and was referred to as the off resonance spectrum. The second 
spectrum or “on resonance spectrum” was collected with the shaped pulse in a 
region of the spectrum that would excite protein resonances but not the ligand 
resonances. A chemical shift between 0 and -2 ppm was usually chosen for the on 
resonance experiment (164). The fact that this ppm range was only sparsely 
populated by protein resonances was not a problem because the saturation that the 
shaped pule imparts on the protein resonances it excites quickly diffuses to all 
protein resonances, so as long as even a small part of the protein was excites with 
the pulse the whole protein became saturated, this happens more efficiently for 
larger proteins (165). If the ligand were to bind to the protein that had been 




This would result in the ligand peaks having a lower intensity in the on resonance 
spectrum. The off resonance spectrum is then subtracted from the on resonance 
spectrum to produce the difference spectrum, so in theory, only the resonances of 
the bound ligand will be present in the difference spectrum (166) although artefacts 
and false positives can occur. Figure 48 gives a cartoon representation of this.  
STD experiments are sensitive to binders with Kds in the range of 10-3 – 10-8 M (160). 
During the saturation time of the experiment ligands need to bind to the protein, 
receive a transfer of saturation and then diffuse off the protein so another ligand can 
bind. Only the free ligand is detected as the bound ligand will produce very broad 
signals as it adopts the long correlation time of the protein it is bound to. If the ligand 
binds too tightly then the rate at which it diffuses off the protein will be very slow so 
new ligands can’t bind to the protein and receive a saturation transfer. This results 
in the population of partially saturated ligand being low so no drop in signal in the 
on resonance spectrum is seen. If the binding is too weak the amount of ligand that 
binds and receive a saturation transfer is low so again, no drop in signal is seen in the 
on resonance spectrum (167). Despite STDs limitations in the direct detection of tight 
binding ligands, a method does exist that uses the displacement of a ligand with an 
STD observable affinity by a much tighter binder to be detected. This works by 
measuring the drop in the signal of the weaker ligand in the difference spectrum 
when the tighter binder is added. By using this method the affinities of different 





Figure 48. Cartoon representation of an STD experiment. A binding ligand is represented in blue and 
a non-binding ligand in red. The peaks with the largest intensity in the difference spectrum were in 
closest proximity to the protein.  The difference spectrum is phased 180⁰ to the off and on 
resonance spectrum. 
Another useful property of STD experiments is that nuclei that are in close proximity 
to the protein show a larger STD effect than the more distant nuclei. This can be used 
in conjunction with protein observe experiments to determine the orientation of the 
ligand in the active site (169). 
5.1.2 2D NMR experiments in ligand binding studies. 
The use of chemical shift perturbation in 2D NMR experiments (1H, 15N HMQC-
SOFAST for example) has been extensively reported (170)(171)(172). The premise is 
that a 2D spectrum of isotopically labelled protein is collected, ligand can then be 
titrated into the sample. If the ligand binds, the residues in close proximity to it will 




different chemical shift. This technique can be used for a range of different 
applications such as determining the Kd of a ligand for a protein (173). If the 2D NMR 
spectra of the protein is assigned and a structure of the protein has been determined 
then the binding site of the ligand can be determined by mapping the peak shifts 
onto the structure, this process can also be used to detect conformational change if 
the residues whose peaks move are in different parts of the protein (174). The 
benefit of protein observe methods is that a proteins response to the binding of the 
ligand can be studied at atomic resolution. The downsides include information on 
how the ligand is effected by binding is not obtained, the need for isotopically 
labelled protein, long acquisition times of 2D experiments, proteins over 30 kDa 
becomes difficult due to the crowded spectra of broad peaks and if detailed 
information on the structural changes in the protein is required, a large investment 
of time is needed to assign the peaks to the each residue (175).  
Tight and week binding ligands can have different effects on the peaks observed in 
the NMR spectra. Week binding ligands will result in fast chemical shift exchange. 
This means that as the concentration of ligand is increased the effected peaks of the 
protein will migrate from the unbound position to the bound position in a dose 
dependent manner. When saturation is achieved the peak will remain in the same 
position. When a tight binding ligand is used the system is in slow exchange and two 
peaks will be present for each of the effected protein residues, one for unbound and 
one for bound. As the concentration of the ligand is increased the unbound peak will 
reduce in intensity and the intensity of the bound peak will increase. Figure 49 
displays this point graphically. OPs are covalent inhibiters so will be in slow exchange, 
however AChE-d was incubated with OPs for a long enough time that the vast 
majority of the sample was inhibited so only one peak is present for each of the 





Figure 49. graphic representation of the different chemical exchange regimes. This Figure is an 
altered version of one found in (176). 
5.1.3 Use of NMR to study AChE. 
Papers have been published that used NMR to study AChE (177)(178)(179), all of 
which have been ligand observe experiments that either tried to identify reversible 
binders to be used as Alzheimers drugs (178) or as an alternative to the Ellman’s 
assay to study the kinetics of AChE (177)(179). No studies could be found that used 
AChE with a mutated active site serine to study the affinities of OPs. This was 
surprising as papers have been published on the effect of mutations on the activity 
of AChE (137) and STD experiments have the potential to not only inform on affinity 
of an OP but also its chemical motifs that interact closely with AChE. As discussed in 
chapter 2, no studies using 2D NMR experiments on isotopically labelled AChE have 
been published. This has meant that the only studies on the effect of OP inhibition 
of AChE structure have been X-ray crystallography based. These studies have 
identified differences in the structure of paraoxon (74) and sarin (180) inhibited 
AChE. In (73) quantitative structure activity relationship regression analysis was used 
to derive an equation to predict the reactivation rate of OPs based on their molecular 
volume, the electronegativity of their chemical groups and their predicted 
orientation in the active site of AChE. The equation produced by this work was 
generally able to predict reactivation rate with enough accuracy to rank the rates 
relative to each other. However, the equation was not successful at predicting the 
reactivation rates of all the tested OPs which indicated that the equation was not 
taking all the necessary parameters into account. It was thought that the changes in 




reactivation rate so it was decided that NMR should be used to try and detect 
perturbation of residues caused by different OPs and see if there was a correlation 
with certain peak shifts and the reactivation rate of different AChE-OP complexes. 
The benefit this would have over the X-ray crystallography method was that the 
solution state of the enzyme would be observed, the data would be quicker to 


















5.2.1 Producing OP inhibited AChE-d samples.  
OP inhibited samples were made using the methods in section 4.2.4 except the AChE-
d concentration was 20 µM instead of 5 µM. The elution was used to make a 350 µl 
sample in phosphate buffer containing 5% D2O with a 14 µM concentration of OP 
inhibited AChE-d. A 5 mm Shigemi tube was used in the data collection.  
5.2.2 Collection and processing of HMQC-SOFAST data. 
HMQC-SOFAST (111) data using azamethiphos, fenamiphos, methamidophos and 
chlorfenvinphos was collected on the NMR machine at Kent described in section 
3.2.2. The data concerning tabun, soman, cyclosarin and VX was collected on an NMR 
spectrometer at Defence Science and Technology Laboratory (DSTL), Porton Down, 
which had the same specifications as the one at Kent.  
1H, 15N HMQC-SOFAST experiments were collected and processed as described in 
section 3.2.2. The AChE-d concentration was 14 µM for all spectra. 
The TOPSPIN software package was used to pick 43 peaks in the HMQC-SOFAST 
spectrum. To decide which peaks to pick two different spectra of un-inhibited AChE-
d were used. These spectra had been collected under identical conditions on two 
separate samples of AChE-d. For a peak to be selected it had to be easily resolved 
from nearby peaks either because of its high intensity or because of its position in a 
sparsely populated region of the spectrum. The peak also had to be seen in both 
spectra of un-inhibited AChE-d, this was done to prevent noise from being mistaken 
as peaks. The two un-inhibited spectra also allowed the peak shift due to normal 
sample variation to be determined. If the peak shifts caused by OP inhibition were 
less than the peak shifts caused by sample variation they were discarded from the 
data set.  
In the spectra of OP inhibited AChE-d the peaks in closest proximity to the position 
of the picked peak in the un-inhibited spectra were picked. The difference in peak 




chemical shifts were adjusted by a factor of 0.26 to account for the different chemical 
shift ranges of 1H and 15N. 
5.2.3 Production of AChE-d Ser 204 -> Ala mutant.  
The active site serine of AChE-d was mutated to an alanine, this was done to produce 
an AChE-d mutant (AChE-d S204A) that would bind to OPs but not form a covalent 
bond with them. The quick change mutagenesis method was used to achieve this. 
The primers in Table 20 were designed to introduce this mutation. The mutagenic 
reaction was carried out using the protocol and reagents supplied by Agilent in their 
QuikChange II Site-Directed Mutagenesis Kit (181). The resulting plasmid was sent 
for sequencing to confirm that only the desired mutation had been introduced. The 
plasmid containing the AChE-d S204A gene was transformed into Shuffle E. coli cells. 
Protein expression and purification was carried out using the same protocol as AChE-
d (Sections 2.2.2 – 2.2.4). The PCR conditions used were 30 cycles of 1 min at 94oC 
for denaturation 2 min at 55oC for primer annealing and 3 min at 72oC for extension. 
Table 20 . The primers used in the quick-change mutagenesis of Ser 204 to Ala in AChE-d. 




5.2.4 STD NMR analysis of OP binding to AChE-d S204A. 
As with the NMR experiments in section 5.2.2, samples containing 
organophosphorus chemical warfare agents were run on the NMR at Porton Down 
and samples containing pesticide OPs were run on the NMR at the University of Kent.  
The samples were made in in phosphate buffer (20 mM sodium phosphate, 100 mM 
NaCl, pH 7.4) containing 0.5 mM OP, 5% deuterated methanol and 5.5 µM AChE-d 
S204A, the final volume was 550 µl. Samples were collected in 5 mm NMR tubes. An 
exponential window function 0.3 Hz was applied to all spectra. 
The STD experiments used 8 dummy and 256 real scans with a time domain of 32768 




the shaped pulse used for saturation was an Eburp2.100 pulse set at -30 ppm for the 
off resonance portion of the experiment and -2 ppm for the on resonance portion. 
All data was collected at 25⁰C. All spectra were phased to 180⁰ from the reference 
spectra so binding was indicated by positive peaks in the difference spectrum.  
To obtain the excitation profile of the Eburp2.1000 shaped pulse, a 550 µl sample of 
D2O in a 5 mm NMR tube was used. In a 1H 1D experiment using the Eburp2.1000 
pulse as the source of excitation, a spectrum was collected for 1 scan every 0.1 ppm 
between 0 and 10 ppm. This was achieved by changing o1p. The intensity of the 
residual water peak was measured in every spectrum and the data was plotted using 
Excel. The experiment was carried out at 25⁰C on the Bruker Avance III 600 MHz (14.1 
Tesla) 4-channel 5-amplifier NMR spectrometer with a QCI-F cryoprobe at the 
University of Kent. 
5.2.5 Measurement of 31P chemical shifts. 
Samples containing organophosphorus chemical warfare agents were run on the 
NMR at Porton Down and samples containing pesticide OPs were run on the NMR at 
the University of Kent. 
The samples were 0.5 mM OP in phosphate buffer containing 5% deuterated 
methanol. The sample volume was 550 µl and all samples were collected in 5 mm 
NMR tubes. 
The 31P experiments used 4 dummy and 512 real scans with a time domain of 131072 
and a spectral width of 396 ppm. Proton decoupling was employed. 19F decoupling 
wasn’t available so the peak position of OPs containing a 19F was measured at the 
midpoint of the two 19F coupled peaks. An exponential window function of 5 Hz was 








5.3.1 HMQC-SOFAST experiments. 
In an attempt to investigate whether inhibition of AChE-d by OPs with different 
reactivation rates caused perturbation of different residues, 1H, 15N, HMQC-SOFASTs 
were collected on un-inhibited AChE-d and AChE-d inhibited by each of the pesticide 
OPs shown in Figure 39, and tabun, soman, cyclosarin and VX (Figure 9 A and B). 
Figure 50 shows the structure of the phosphate adducts that were left bound to Ser 
204 of AChE-d after inhibition with each of these OPs. Because unreacted OP was 
removed, these adducts would be responsible for any perturbation of residues seen 
in the NMR spectra of inhibited AChE-d.  
 
Figure 50. The phosphate adducts left bound to the active site serine of AChE-d after inhibition with 
different OPs. The aged form of soman is shown as this is rapidly produced after inhibition. 
Figure 51 shows the peaks in the 1H, 15N HMQC-SOFAST that were chosen to assess 
the impact of OP inhibition on AChE-d. As AChE-d spectra were not assigned, if a peak 
moved after inhibition its new location could not be determined with any certainty. 
When comparing the spectra of uninhibited and inhibited AChE-d, the peak in the 
inhibited spectrum that was closest in proximity to the position of the peak in the 
uninhibited spectrum was picked. In an attempt to assess the variability of the 
measurements, a 1H, 15N HMQC-SOFAST was collected on two different samples of 
un-inhibited AChE-d that had undergone identical treatment. The differences in peak 
position between the two spectra were recorded and provided values for the 




magnitude of a peak shift caused by OP inhibition was lower than the peak shift 
between the two un-inhibited spectra it was discarded. Figure 52 shows the two un-
inhibited spectra of AChE-d overlaid, the reproducibility was poor as not all peaks 
were in the same place. The cause of this was not known but noise was likely to be a 
significant factor. Only peaks that were in the same position in both spectra were 
picked to try and limit the effect the poor reproducibility would have had on the data. 
Figure 53 shows an example of the peak picking process and highlights the main 
problem associated with the method. In the chlorfenvinphos inhibited spectrum one 
peak was in the closest proximity to the positions of peak 41 and 42 in the 
uninhibited spectrum so it was picked as both of these peaks in the chlorfenvinphos 
inhibited spectrum. This was because the true position of either peaks could not be 
determined, it did not indicate that the two peaks had merged.  Figure 54 shows the 
magnitude of the peak shift caused by each of the OP adducts in Figure 50 minus the 
shifts that were smaller than those between the two un-inhibited spectra. The 
magnitudes were useful in determining peak shifts that were larger than what could 
be expected by sample variation but, because the position of each peak could not be 
accurately determined after inhibition the magnitudes were not necessarily accurate 
representations of the peaks that had moved the most. For this reason the data was 
analysed on a binary basis with peaks being classed as having shifted or not based 





Figure 51. 1H, 15N HMQC-SOFAST of AChE-d with the position of the 43 peaks used to asses AChE-d 
inhibition indicated by red crosses. The concentration of AChE-d was 14 µM. The spectrum was 
collected for 1888 scans with 1024 points in the 1H dimension and 100 points in the 15N dimension 
at 35 ⁰C. The noise base level was set to 26905.6. 
If two OPs caused the same peak to shift this was classified as a peak shift in common. 
The number of peak shifts that each of the OPs had in common were counted (Table 
21 and Figure 55), this was done to identify OPs that caused similar residue 
perturbations. The mean number of peak shifts in common was 22.3 ± a standard 
deviation of 4.3 so OPs that had more than 27 peak shifts in common had an above 
average similarity. These OP pairs and their number of shared peak shifts were, 
tabun – fenamiphos 28, azamethiphos – chlorfenvinphos 29, and chlorfenvinphos – 
fenamiphos 31. There were 12 peaks that all tested OPs caused a shift in, their peak 





Figure 52. Overlay of the 1H, 15N HMQC-SOFAST spectra of 2 different but identically treated un-
inhibited AChE-d samples. The concentration of AChE-d was 14 µM. The spectra were collected for 
1888 scans with 1024 points in the 1H dimension and 100 points in the 15N dimension at 35 ⁰C. The 






Figure 53. Overlaid 1H, 15N HMQC-SOFAST spectra of un-inhibited AChE-d (blue) and 
chlorfenvinphos inhibited AChE-d (gray). Arrows indicate assumed movement of the peaks between 
the two spectra.  
The number of peak shifts each OP caused was also measured (Table 22). It was 
interesting to note that the OPs with the most peak shifts in common were also the 
ones with the most peak shifts. This could have indicated that the above average 
number of shared peak shifts was actually caused by the higher probability of having 
shared peaks due to these OPs having more peak shifts. However, even if this was 
the case the fact that these OPs caused a larger number of peak shifts was in itself a 





Figure 54. Magnitude of the peak shifts in 1H, 15N HSQC-SOFAST spectra caused by inhibition of 
AChE-d with OPs. The control data is the difference in peak position between two un-inhibited 
spectra of AChE-d. Any peak shift magnitudes that were smaller than the control data for a given 
peak were discarded. 
If OPs with similar reactivation rates caused similar peak shifts then azamethiphos, 
fenamiphos and chlorphenvinphos should have had more peak shifts in common 
with each other than with methamidophos as the kr of methamidophos for both 
oximes was close to 1 min and the other pesticides had kr values ranging from 0.001 
– 0.049 min meaning that methamidophos was much more susceptible to 
reactivation than the other 3 pesticides. Peaks 20, 37 and 38 were found to shift in 
the spectra of AChE-d inhibited by azamethiphos, fenamiphos and chlorfenvinphos 
but not methamidophos. Out of the pesticide OPs methamidophos was the only one 
that caused peak 27 to shift.  
The reactivation data for the organophosphorus chemical warfare agents was 
collected on human erythrocyte AChE and as discussed in section 4.4.3 this could 
mean that the ranking of relative reactivation rates of these OPs might be different 




































was seen in a study using rat brain AChE (182) which suggests that their reactivation 
rates relative to each other are independent of AChE isoform. Assuming that AChE-
d inhibited with VX and cyclosarin is relatively susceptible to reactivation and AChE-
d inhibited with tabun is highly resistant, as seen with other AChE isoforms, then VX 
and cyclosarin should have had more peak shifts in common with each other than 
with tabun. The 1H, 15N HMQC-SOFAST data showed that no peaks shifted in 
response to inhibition with cyclosarin and VX but not tabun. Tabun caused peak 5, 
13, 20, and 21 to shifts, the other two OP chemical warfare agents did not. Soman 
could not be reactivated due to its fast ageing rate (183).  
Table 21. The number of peak shifts that each OP had in common with all other tested OPs. 
 
Soman Tabun Cyclosarin VX Azamethiphos Methamidophos Chlorfenvinphos Fenamiphos 
Soman 
 
25 18 19 23 24 25 27 
Tabun 25 
 
19 19 25 22 26 28 
Cyclosarin 18 19 
 
18 18 18 18 20 
VX 19 19 18 
 
17 18 17 17 
Azamethiphos 23 25 18 17 
 
25 29 26 
Methamidophos 24 22 18 18 25 
 
27 26 
Chlorfenvinphos 25 26 18 17 29 27 
 
31 






Figure 55. The number of peak shifts in common that each OP pair had, a red line at 27 was included 









Table 22. The number of peak shifts in the 1H, 15N HSQC-SOFAST spectra of AChE-d inhibited by each 
of the OPs. In total 43 peaks were picked. The 1H, 15N HMQC-SOFAST spectra of OP inhibited AChE-
d can be seen in appendix 1 – 9. 










5.3.2 STD analysis of OP binding to a mutated isoform of AChE-d. 
Studying the reversible formation of the OP AChE-d complex had an inherent 
problem in that after an OP bound to AChE-d the phosphorylation of the active site 
serine occurred creating a new covalent complex. To overcome this, a mutant of 
AChE-d was made that had the active site serine mutated to an alanine. The 
hypothesis was that as none of the residues in the active site gorge were mutated 
the effect on the binding of an OP to AChE-d would be minimally affected, and 
because the alanine had no hydroxyl group no phosphorylation would occur. The 
mutant was confirmed to have no AChE-d activity by incubating a 1 µM sample of 
the protein in Ellman’s buffer for 10 minutes, no increase in the absorbance at 412 
nm could be detected. This mutant would allow us to only study the reversible part 
of the interaction of OPs with AChE-d. The mutated isoform of AChE-d was termed 
AChE-d S204A.  
The excitation profile of the Eburp2.1000 pulse used in the STD experiment to 
selectively excite AChE-d S204A is shown in Figure 56. The tip of the peak which 
provided maximal saturation of any resonances it hits was relatively small (around 
0.2 ppm), but the total peak including the base covered roughly 2 ppm and a small 




1 and 9 ppm. When using this shaped pulse some saturation of the OP was to be 
expected because the point of maximal excitation needed to hit a protein resonance, 
these usually extend out to around -2 ppm. Any OP peak within 4 ppm of the point 
of maximal excitation (-2 ppm in this case) would be partially excited by the pulse.  
 
Figure 56. The excitation profile of the Eburp2.1000 shaped pulse centred on the water peak. This 
is the shaped pulse used to selectively excite proteins in STD experiments.  
To identify false positive results, control experiments were done for all OPs, these 
involved running the STD experiments on samples containing only the OP. If the 
control experiments gave a positive result it confirmed that the Eburp2.1000 pulse 
was hitting the ligand. This was not a problem in all cases as if a larger STD effect was 
seen when the protein was added binding was confirmed (184). Figure 57 shows an 
example of this, a small peak in the STD spectra of only chlorfenvinphos can be seen 
at around 1.2 ppm (marked with red asterisk in Figure 57). In the STD spectrum of 
chlorfenvinphos and AChE-d S204A the peak becomes considerably larger. Because 
the chlorfenvinphos concentration and STD parameters were identical between the 









































Figure 57. STD NMR experiment of chlorfenvinphos in the presence and absence of AChE-d S204A. 
Chlorfenvinphos concentrations were 0.5 mM and AChE-d S204A was 5.5 µM. The spectra were 
collected over 256 scans. The peak at 1.2 ppm in the control spectrum is marked with a red asterisk.  
Another type of artefact often seen in STD spectra is intense peaks being present in 
the difference spectrum, this can occur if a peak has slight differences in its position 
in the on and off resonance experiments so subtraction of the off resonance 
experiment from the on resonance experiments doesn’t totally remove the peak 
from the difference spectrum (164). This can be seen in Figure 57 as the methanol 
peak at around 3.2 ppm. These artefacts had a consistent intensity in the samples 
that did and did not contain protein so all changes in peak intensity seen in the OP 
peaks could be attributed to binding.  
Binding of azamethiphos, chlorfenvinphos, VX and VM to AChE-d S204A could be 
detected by STD NMR (Table 24). No binding was detected for Fenamiphos, 
methamidophos and cyclosarin. The data for tabun was inconclusive as the molecule 
broke down rapidly meaning there was only a low concentration of tabun in the NMR 
tube so even if it was binding to AChE-d S204A with an appropriate Kd its 




It was interesting that binding was detected with VX and not cyclosarin because 
cyclosarin has been shown to inhibit human erythrocyte AChE at 4 times the rate of 
VX (65) so it was assumed to be a tighter binder. To test whether cyclosarin was 
binding AChE-d S204A too tightly to be detected by STD NMR a competition 
experiment was set up. For this 0.5 mM of VX and cyclosarin were mixed with AChE-
d S204A and an STD experiment was performed with identical parameters as before. 
If cyclosarin had a higher affinity for AChE-d S204A than VX, the VX signal in the 
difference spectrum would be reduced (185) as cyclosarin would displace it in the 
active site of AChE-d S204A. As indicated by Figure 58 cyclosarin did not displace VX 
from the active site of AChE-d S204A as the VX signal at 1.4 ppm in the difference 
experiment with and without cyclosarin had the same intensity. 
Table 24. Detection of binding of each OP to AChE-d S204A by STD NMR. The STD NMR spectra can 
be seen in Appendix 10-16, and Figure 57. 
 
 














Figure 58. STD data for the competition binding experiment between cyclosarin and VX for AChE-d 
S204A. OP concentrations were 0.5 mM and AChE-d S204A was 5.5 µM. The spectra were collected 
over 256 scans. In the off resonance spectrum the VX peaks are marked with blue asterisk and the 
cyclosarin peaks are marked with red asterisk.  
5.3.3 31P NMR spectra of OPs. 
The electronegativity of the phosphate adducts was thought to affect their 
susceptibility to reactivation by oximes. The 31P chemical shift is highly dependent 
on the electronegativity of the atoms in the phosphate adduct (186) so the chemical 
shift of the 31P atom in the phosphate adduct was thought to be a good proxy to 
assess the electronegativity of the adduct. Attempts were made to inhibit AChE-d 
with OPs and then measure the 31P chemical shift of the phosphate adducts bound 
to the protein. The hypothesis was that 31P atoms that had more electronegative 
surroundings would show higher chemical shifts and in turn be more susceptible to 
reactivation by oximes. No phosphate signals could be detected in the NMR spectra 
of OP inhibited AChE-d even after running the experiments overnight (21000 scans), 
this was likely because of limited concentration of the samples (40 µM), and the large 




Measuring the 31P chemical shift of the phosphate adduct covalently bound to the 
active site serine of AChE-d would have given the value that was most relevant to 
oxime reactivation but because this didn’t appear to be practical the 31P chemical 
shifts of the OPs were measured (Table 25). 
Table 25. The 31P chemical shifts of several OPs.  











The 31P chemical shifts were plotted against reactivation rate (Figure 59 A and B). 
The data in Figure 59 A and B was not combined into a single graph because AChE-d 
was used to obtain the reactivation data of the pesticide OPs (Figure 59 A) at room 
temperature and the data in Figure 59 B was collected at 37⁰C using human 
eurythrocite AChE (65), so as discused in chapter 4, the data were not directly 
comparable. However, it can be seen that in general OPs with higher 31P chemical 





Figure 59. (A) The 31P chemical shifts of azamethiaphos, Fenamiphos, methamidophos and 
chlorfenvinphos plotted against their reactivation rates by two different oximes. Reactivation rates 
were obtained using AChE-d (section 4.3.4). (B) The 31P chemical shifts of tabun, cyclosarin and VX 
plotted against their reactivation rates by two different oximes, the reactivation rates were 




5.4 Discussion.  
5.4.1 1H, 15N HMQC-SOFAST analysis of AChE-d inhibition. 
The peaks that proved easiest to measure were those with a higher than average 
intensity. The fact that these peaks had higher than average intensities indicated that 
they were in a flexible and or disordered region of the protein, for instance the C-
terminus. This flexibility would impart longer T1 and T2 relaxation times on the nuclei 
of these residues meaning they would relax at a slower rate so more signal could be 
detected (176). The active site gorge of AChE-d was not expected to have a higher 
than average flexibility compared to the rest of the enzyme (187) so the easiest to 
measure residues were unlikely to be the ones directly interacting with the 
phosphate adduct. Despite this several peak shifts were identified that were larger 
than the shifts seen between the two un-inhibited spectra. The peaks that shifted in 
all OP inhibited AChE-d spectra (peaks 9, 11, 12, 15, 16, 17, 18, 25, 34, 36, 39, and 
41) were likely to be close to the active site serine which would explain why they 
were perturbed by all the OP adducts. Peaks 15, 16, 17 and 18 were in a region of 
the spectrum where it is common to find the peaks of Asn and Gln side chains (188). 
Gln 71 and Asn 87 both form part of the active site gorge (Figure 60) so were likely 
candidates for at least 2 of these peaks. 
Peaks 41, 42 and 43 were in a region of the spectrum usually populated by the side 
chains of Trp residues (188) and as Figure 61 shows, 5 Trp residues were in close 
proximity to the Ser 204 residue. It was highly probable that some of these Trp 
residues were the 3 peaks in question.  
These peaks could be useful to monitor when trying to detect if a ligand had bound 
to AChE-d, but in this work the aim was to see if OPs with similar reactivation rates 
caused similar peak shifts. These peaks were not particularly useful for this task as 
they shifted after inhibition by all OPs, regardless of the reactivation rate of the OP.  
The number of peak shifts caused by each OP should have been related to the size 
of the phosphate adduct left by the OP as a larger adduct would interact with more 




volumes and the volume estimates of the insecticide OPs adducts that were 
calculated in section 4.3.4. Cyclosarin was expected to cause the most shifts in the 
1H, 15N HSQC spectra as it had the largest volume but in reality it produced the lowest 
number of shifts (VX and fenamiphos) (Table 22). Chlorfenvinphos showed the 
largest number of shifts even though it had an estimated adduct volume of 13150 
nm3 which was very close to the median adduct volume of 12152 nm3. When the 
estimated volume of the phosphate adducts were plotted against the number of 
peak shifts they caused (Figure 62) no correlation was seen. This indicated that the 
size of the phosphate adduct was not a good indicator of how many residues it would 
perturb. One reason for this could be that the active site gorge had enough room to 
accommodate even the larger adducts without any perturbation of the residues and 
it is the electronegativity of groups of the adduct that determine how residues 
interact with the adduct so in turn how many peaks shift. 
 
Figure 60. The base of the active site gorge of AChE-d with S204 in pink, Q71 in orange and N87 in 
blue. The PDB structure with id number 4pqe was used to generate this image. 
Several peaks were identified that only appeared to shift in the spectra of AChE-d 
inhibited with OPs that had slow reactivation rates for pralidoxime and obidoxime. 




organophosphorus chemical warfare agents as their reactivation rates were 
collected using the human erythrocyte isoform of AChE so these OPs could have 
different reactivation rates with AChE-d. Even the data collected on the insecticide 
OPs have problems that limit the conclusions that can be drawn from it. For instance, 
when the data is viewed in a binary way with peaks being classed as shifted or not 
shifted, a difference does seem to exist between the peaks shifted by OPs with 
different reactivation rates. It would be tempting to say that this is evidence that 
interaction of an adduct with certain residues can confer a certain degree of 
protection from reactivation. However, when the peak shifts are viewed on the NMR 
spectra the difference becomes less convincing. As can be seen in Figure 63, the shifts 
in the position of peaks 37 and 38 caused by inhibition with chlorfenvinphos and 
methamidophos were similar in magnitude but only the shifts caused by 
chlorfenvinphos were deemed significant as they were slightly larger. The small 
difference between peak shifts that were deemed significant (chlorfenvinphos) and 
insignificant (methamidophos) meant that factors like noise could potentially result 
in peaks either being included in the list of significant shifts or not. This problem was 






Figure 61. The active site gorge of AChE with Ser204 in pink and 5 Trp residues that were in close 
proximity to the Ser in cyan. The PDB structure with id number 4pqe was used to generate this 
image. 
Table 26. Volume estimates for the phosphate adducts left bound to AChE-d after inhibition by each 
of the OPs. The volume estimates are ordered largest to smallest. The volume of somans aged form 
is given as the ageing process happens with a half-life of around 4 minutes (144) so the aged form 
would have been present in the 1H, 15N HMQC-SOFAST experiment. 




Cyclosarin O2PC7H14 16710 
Fenamiphos O2PH13NC5 15045 
Tabun O2PH11NC4 13515 
Chlorfenvinphos O3PH10C4 13150 
Azamethiphos O3PH6C2 12890 
VX O2PC3H8 10720 
Methamidaphos O2PH5NC 8925 






Figure 62. The estimated volume of the phosphate adducts of each on the OPs plotted against the 








Figure 63. HMQC-SOFAST of un-inhibited AChE-d (blue), methamidophos inhibited AChE-d (pink) 
and chlorfenvinphos inhibited AChE-d (black). The protein concentration was 14 µM in all samples. 
The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in 
the 15N dimension at 35 ⁰C.  
5.4.2 Assessment of OP binding using STD NMR. 
The fact that VX had a higher affinity for AChE-d S204A than cyclosarin was surprising 
as cyclosarin has been shown to inhibit AChE-d at a faster rate than VX in multiple 
isoforms of AChE (182)(65). This suggests that cyclosarin must be much more 
reactive to the active site serine of AChE than VX to make up for its lower affinity. 
Cyclosarin has F as a leaving group which has been shown to be a better leaving 
group than the 2-(diisopropylamino)ethane-1-thiol of VX. This is likely to account for 
the faster inhibition rate seen with cyclosarin.  
STD NMR can reportedly detect binders with affinities ranging from around 10-3 – 10-
8 M (189), this indicated that cyclosarin had a mM Kd for AChE-S204A which is 
remarkably weak for a compound that has an LD50 of 21.9 µg/kg (intravenous in pigs) 




it must have to spend a considerable amount of time bound to the enzyme but not 
reacting with it, so the assumption can be made that the rate limiting step in the 
reaction of VX with AChE-d is the phosphorylation of the active site serine. Since 
cyclosarin was a relatively weak binder but had a faster inhibition rate, it can be 
assumed that the phosphorylation of the active site serine is the rate limiting step 
for this OP as well. It was not completely unsurprising that methamidophos and 
Fenamiphos binding could not be detected as they were both shown to be relatively 
poor inhibitors of AChE-d in section 4.3.2. It would be interesting to compare the 
binding affinities and inhibition rates of more OPs to see if the trend of 
phosphorylation being the rate limiting step is common to all OPs. Whilst the STD 
data gave some insight into the mechanism of OP inhibition it did not provide useful 
predictions on the toxicity of OPs as soman and cyclosarin showed no binding but 
were both highly toxic. 
As AChE-d is not completely representative of wild type AChE, interpretation of the 
data requires care as there is the possibility that VX inhibits AChE-d at a faster rate 
than cyclosarin. AChE-d S204A had the added problem that a key residue in the 
enzyme was mutated, this would have affected the affinity of the OPs for the 
enzyme, but the degree of the affect is unknown. 
5.4.3 31P NMR. 
The chemical shift of the 31P signal of an OP appeared to be a relatively good indicator 
of how susceptible the OP would be to reactivation by pralidoxime and obidoxime. 
The 31P chemical shift was measured with the leaving group still attached to the OPs, 
this would have introduced a source of error as the leaving group would contribute 
to the chemical shift of the OP but was not present on the phosphate adduct that 
inhibits AChE-d. So the chemical shift measured were not completely representative 
of the phosphate adducts. A closer correlation could potentially be obtained by 
measuring the 31P chemical shift of the phosphate adduct bound to AChE-d. High 
concentrations of the inhibited protein would be needed and a higher field NMR 
spectrometer would also improve the likelihood of detecting the adduct by 




The 31P spectra should have given an indication of the inhibition rates of the OPs 
because OPs with higher 31P chemical shifts would have had a more de-shielded 31P 
nucleus meaning it would be more susceptible to nucleophilic attack by the O of the 
active site serine. As Table 25 shows the 31P chemical shifts were poor indicators of 
the inhibition rate of the OPs. Chlorfenvinphos had the lowest chemical shift (-6.51 
ppm) but inhibited AChE-d faster than fenamiphos and methamidophos which had 
chemical shifts of 6.79 and 42.56 ppm respectively. This indicated that the leaving 
group and structure of the OP were likely to be the determining factors of the 





















Chapter 6. General conclusions. 
6.1 Summary of thesis. 
The expression and purification of a designed isoform of human acetylcholinesterase 
(AChE-d) was optimised resulting in the recovery of around 2 mg of purified AChE-d 
for every litre of Shuffle E. coli grown in 2YT media. Different isotopic labelling 
schemes were investigated as follows. Uniform 15N labelling, specific 15N labelling of 
I, L and V residues, specific 15N un-labelling of all residues apart from I, L, V, W and C, 
specific 19F labelling of W and F residues and uniform 15N and 2H labelling. Uniform 
15N labelling produced around 0.6 mg of purified AChE-d for every litre of Shuffle E. 
coli grown in minimal media. Specific 15N labelling of I, L and V residues only 
produced 10s of µg/l of AChE-d, most likely because an inhibiter of the enzyme that 
transfers amino groups between residues was added which appeared to be toxic to 
the cells. The un-labelling method produced around 3 mg/l of purified AChE-d, well 
resolved peaks on the periphery of the NMR spectrum were lost and several well 
resolved peaks in the central region of the spectrum were gained (Figure 36). All the 
19F labelled precursors for W and F residues caused a drop in AChE-d expression 
ranging from a 40 % to a 98 % reduction in the AChE-d activity in the lysate 
supernatant, when an NMR sample was made using AChE-d labelled with the 
precursor that caused the smallest drop in activity (4-fluorophenylacetic acid), no 
signal could be detected in the 1D 19F NMR spectrum. Attempts to uniformly label 
AChE-d with 2H as well as 15N resulted in around 60 µg/l of AChE-d being produced. 
Uniform 15N labelling of AChE-d was chosen as the best method of labelling AChE-d 
as it produced a relatively good yield of protein and the NMR spectra of this protein 
had more well resolved peaks than protein produced using the un labelling method. 
The kinetics of the inhibition of AChE-d by four organophosphate (OP) pesticides 
(Figure 39) were studied and the results were compared with the data published in 
(65) which presented the inhibition and reactivation rates of human erythrocyte 
AChE by methamidophos, Fenamiphos, paraoxon-methyl and paraoxon-ethyl. In this 




chlorfenvinphos respectively as the paraoxons were deemed to be too toxic. 
Paraoxon-methyl leaves the same phosphate adduct bound to AChE-d after 
inhibition as azamethiphos, the same is true for paraoxon-ethyl and chlorfenvinphos. 
The OP pairs that have the same phosphate adduct will give the same result in 
reactivation experiments as the phosphate adduct is what gets covalently attached 
to the active site serine of AChE-d so is the only relevant part of the OP. However, 
these OP pairs will not have the same inhibition rates as the leaving groups are 
different which will alter the affinity and reactivity of the OP for the AChE-d active 
site. Methamidophos was shown to be a more potent inhibitor than fenamiphos for 
both AChE-d and human AChE. This could indicate the two AChE isoforms have the 
same relative susceptibilities to inhibition by OPs but more OPs would need to be 
tested to confirm this. Based on methamidophos and fenamiphos alone the data in 
(65) concerning organophosphorus chemical warfare agents could not be assumed 
to be representative of AChE-d. The same analysis was done with the reactivation 
rates of two oximes (Figure 38) for AChE-d inhibited with each of the OPs and the 
two isoforms were shown to follow different trends (Table 27).  
Table 27. Relative ranking of the reactivation rates of AChE-d and human AChE inhibited by OPs. 
Paraoxon-methyl has the same phosphate adduct as azamethiphos meaning that AChE inhibited by 
these OPs are identical. The same is true for paraoxon-ethyl and chlorfenvinphos. The data for 
reactivation of OP inhibited human AChE was taken from (65). 
Reactivation rate OP inhibited AChE-d OP inhibited human AChE 
Fast Methamidophos Paraoxon-methyl 
 Azamethiphos Methamidophos 
 Chlorfenvinphos Paraoxon-ethyl 
Slow Fenamiphos Fenamiphos 
 
Using identical conditions, 1H, 15N HMQC-SOFAST spectra were obtained of AChE-d 
inhibited with four pesticides and four organophosphorus chemical warfare agents 
and the peak shifts caused by the inhibition were measured. The OPs that had the 
slowest reactivation rates appeared to cause the most peak shifts and have more 




However, the magnitudes of the peak shifts were small and the concentration of 
protein was low (14 µM) which meant noise due to sample variation and hardware 
limitations could have had a substantial influence on results. Figure 64 shows the 1H, 
15N HSQC spectra of lysozyme in the presence of different concentrations of 
histamine, black arrows show the significant peak shifts which were several times 
larger than those seen in this work (Figure 63 for example). When it comes to using 
protein observe NMR to study ligand binding, lysozyme has an advantage over AChE-
d, lysozyme is around 14 kDa meaning its spectra is much less crowded and its peaks 
much sharper so movement of the peaks is easier to track. 
The active site serine of AChE-d was mutated to an alanine, this produced a variant 
of AChE-d (AChE-d S204A) that could bind to OPs but not be phosphorylated by them. 
Saturation transfer difference NMR was used to study the binding between AChE-d 
S204A and OPs. Binding could not be detected for all OPs and, for cyclosarin it was 
shown that the lack of signal in the STD spectra was not due to the binding being too 
tight which indicated that cyclosarin had a very low affinity for AChE-d.  
The 31P NMR spectra of OP inhibited AChE-d were collected but no signal could be 
detected. This was likely due to the large size of AChE-d (62.517 kDa) making the 
peak of the phosphate adduct very broad, and together with the low concentration 
of the sample (40 µM), resulting in low signal intensity. 31P NMR spectra have 
successfully been collected on a 42 kDa protein but a concentration of around 800 
µM was used (192). Getting an 800 µM sample of OP inhibited AChE-d was not 
feasible so the 31P spectra of the OPs were collected instead. The OPs with faster 





Figure 64. Natural abundance 15N, 1H HSQC spectra of a 5 mM lysozyme sample with different 
concentrations of histamine. The ratio of lysozyme to histamine is shown in the top left hand corner. 











6.2 Outcomes of the project. 
As outlined in section 1.3.3 of the thesis, the aims of this project were to: 
• Find a cost-effective source of high purity AChE with the highest possible similarity 
to wild type human AChE-S. 
 
• Develop NMR methods to study the interactions of AChE with a range of OPs, and to 
develop protocols for use in assessing the threat of any newly discovered OPs. 
 
• To gain data on the mechanism of inhibition and reactivation that could be used to 
understand whether inhibition of AChE by certain OPs causes structural changes in 
the protein that could lower the affinity of certain oximes for that particular OP AChE 
conjugate. This would help to explain the different reactivation rates that oximes 
have for different OP AChE conjugates. 
In Chapter 2 it was clearly demonstrated that pure AChE-d could be obtained after 
recombinant expression in E. coli, the benefit this had over the recombinant 
expression in insect (90) and mammalian cells (89) was that isotopic labelling could 
be carried out in a cost effective manner. The downside of using an E. coli expression 
system was that only AChE-d could be expressed. This isoform was shown to have an 
11% reduction in the turnover rate of ATCh when compared to human AChE (80). In 
Sections 4.3.2 and 4.3.4 it was shown that the relative ranking of the reactivation 
rates of pesticide inhibited AChE-d by oximes differed from the ranking of 
reactivation rates in human AChE. So AChE-d was shown to not be completely 
representative of human AChE but as it was the only isoform that could be 
isotopically labelled its use was continued and all data had to be interpreted with 
this caveat in mind.  
Both protein and ligand observe NMR methods were developed. Attempts to 
simplify the NMR spectrum of AChE-d were unsuccessful which resulted in low 
resolution 1H, 15N HMQC-SOFAST spectra of uniformly 15N labelled AChE-d being 




slow reactivation rates may produce different peak shifts in the NMR spectra than 
OPs with fast reactivation rates, but due to the low resolution and signal-to-noise of 
the spectra, definitive conclusions could not be draw from the data. Although this 
method could potentially identify residues important in protecting OPs from 
reactivation it is unlikely to have any predictive value in estimating OP toxicity as no 
correlation was seen between peak shifts caused by an OP and its toxicity. The ligand 
observe method using STD NMR and AChE-d S204A was able to detect the binding of 
some OPs to the mutated enzyme, but the fact that the binding of all OPs could not 
be detected meant that STD NMR was not useful in estimating the toxicity of an OP 
because highly toxic OPs like soman and cyclosarin did not show any binding. Due to 
the low signal to noise (around 3:1) of the STD experiments the relative intensities 
of the peaks in the difference spectrum could not be analysed to determine a 
chemical group’s proximity to the enzyme, so chemical groups that had close 
interactions with the enzyme could not be identified.  
The resolution and signal to noise of the 1H, 15N HMQC-SOFAST spectrum was low, 
so although a larger number and similar peak shifts were seen in AChE-d inhibited 
with slow reactivating OPs, the results need to be viewed with cation. With this in 
mind, the data could be seen as preliminary evidence that interaction of a phosphate 
adduct with certain residues can have a protective effect against oxime-mediated 
reactivation. The STD data indicated that the phosphorylation step in the inhibition 
of AChE-d was the rate limiting part of the reaction so the affinity of the OP for AChE-








6.3 Future work. 
Obtaining the inhibition and reactivation rates for the organophosphorus chemical 
warfare agents with AChE-d should be a main priority as the relative ranking of these 
values for several OPs was shown to be different for AChE-d and human AChE. This 
introduced problems in interpreting the AChE-d 1H, 15N HMQC-SOFAST spectra of OP 
chemical warfare agent inhibited AChE-d as the only available kinetic data for 
organophosphorus chemical warfare agents was produced with human AChE. This 
meant that the OPs could not definitively be classed as having a fast or slow 
reactivation rate, and as one of the aims of this work was to look for common peak 
shifts in OPs with common kinetic parameters, the kinetic parameters need to be 
clearly defined.  
Attempts should also be made to express usable quantities of deuterated AChE-d as 
this would allow more detailed NMR studies of the enzyme to be undertaken. In this 
work the only method of deuteration tried was the “condense and grow” method 
(119) in which E. coli is grown in 3 L of rich media to an OD600 of round 0.6. These 
cultures are then centrifuged, and the cell pellets are washed with phosphate buffer 
then re-suspended in 1 L of D2O minimal media, recombinant expression is then 
induced after a 45 minute equilibration period. E. coli need to alter their protein 
composition to survive in D2O growth media (122) so the abrupt change from 
protonated to deuterated media used in this method could stress the E. coli cells, 
reducing the yield of recombinant protein. Other deuteration methods equilibrate E. 
coli to D2O by growing the cells in minimal media with a gradually increasing 
percentage of D2O. First the cells are grown in minimal media containing 50% D2O, 
once the culture reaches stationary phase cells are spreads on an agar plate 
containing 50% D2O. A colony from this plate is used to inoculate a 90% D2O minimal 
media culture which is then used to produce colonies to inoculate a 100% D2O 
culture (194). This method selects for cells that can tolerate D2O and will result in 
cells having the necessary proteome to grow in D2O at the start of the experiment 





If AChE-d was successfully deuterated then the assignment of the backbone residues 
could become possible. The largest enzyme that has been assigned is malate 
synthase which has a molecular weight of 81 kDa (195). However, malate synthase 
was likely chosen for assignment as it produced unusually good NMR spectra for a 
protein of its size, the samples also had a concentration of 900 µM. Achieving a 
concentration that high with AChE-d is unlikely to be feasible. If the 1H, 15N spectra 
of deuterated AChE-d was not assignable, then the selective 13C labelling of 
Isoleucine, leucine and valine (ILV) could be investigated. This involves expressing 
the protein in the presence of ILV precursors that have the methyl group selectively 
13C labelled and all protons apart from those of the methyl replaced with deuterons. 
In a 1H, 13C NMR spectra one peak will be observed for each of the ILV residues (196) 
resulting in a greatly simplified spectra. Assigning the spectrum of deuterated AChE-
d with either uniform 15N or ILV 13C labelling would involve a substantial amount of 
work and there is no guarantee it is possible. However, if successful, studying the 
dynamics of AChE-d would become easier which would lead to valuable information 
on how AChE-d is structurally affected by inhibition and reactivation. There is clearly 
an appetite for this type of research as papers are routinely published that use X-ray 
crystallography and computer simulations to study the structural dynamic of human 
AChE. Some examples are, estimating the flexibility of aromatic residues in the gorge 
(197), and estimating how fluctuations in the volume of the active site gorge after 
inhibition with different OPs could affect reactivation (198). Other studies have taken 
a purely computational simulation approach to try and understand the protein 
structural changes that are important for the inhibition by OPs (199) and their ageing 
(144). NMR could enhance these studies by providing information on dynamics and 
the residues that interact with OPs and oximes, this data could be used as 
refinements in molecular dynamics simulations and to validate X-ray crystallography 
data. This could aid the rational design of safer OP insecticides and Alzheimer’s drugs 
and more effective oxime reactivators.  
The mutation introduced into AChE-d S204A would have had an effect on the binding 




the Kd of several reversible inhibitors (Alzheimer’s drugs for example) should be 
determined using AChE-d and AChE-d S204A. 
The inhibition rates of OPs did not correlate with their toxicity, because of this it was 
thought that their degradation in vevo could influence toxicity. To better predict OP 
toxicity their breakdown by cytochrome p450, glutathione s transferase and 
paraoxonases should be investigated using in vitro assays as these enzymes are 
known to breakdown OPs in organisms (200). It is possible that the less toxic OPs are 
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8.1  1H, 15N HMQC-SOFAST of OP inhibited AChE-d. 
 
Appendix 1. 1H, 15N HMQC-SOFAST of soman inhibited AChE-d with the position of the 43 peaks 
used to asses AChE-d inhibition indicated by black crosses, the concentration of AChE-d was 14 µM. 
The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in 





Appendix 2. 1H, 15N HMQC-SOFAST of tabun inhibited AChE-d with the position of the 43 peaks used 
to asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 µM. The 
spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in the 








Appendix 3. 1H, 15N HMQC-SOFAST of cyclosarin inhibited AChE-d with the position of the 43 peaks 
used to asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 µM. 
The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in 








Appendix 4. 1H, 15N HMQC-SOFAST of VX inhibited AChE-d with the position of the 43 peaks used to 
asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 µM. The 
spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in the 








Appendix 5. 1H, 15N HMQC-SOFAST of un-inhibited AChE-d with the position of the 43 peaks used to 
asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 µM. The 
spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in the 








Appendix 6. 1H, 15N HMQC-SOFAST of azamethiphos inhibited AChE-d with the position of the 43 
peaks used to asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 
µM. The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points 








Appendix 7. 1H, 15N HMQC-SOFAST of methamidophos inhibited AChE-d with the position of the 43 
peaks used to asses AChE-d inhibition indicated by black crosses, the concentration of AChE-d was 
14 µM. The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 








Appendix 8. 1H, 15N HMQC-SOFAST of chlorfenvinphos inhibited AChE-d with the position of the 43 
peaks used to asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 
µM. The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points 








Appendix 9. 1H, 15N HMQC-SOFAST of fenamiphos inhibited AChE-d with the position of the 43 peaks 
used to asses AChE-d inhibition indicated by red crosses, the concentration of AChE-d was 14 µM. 
The spectrum was collected for 1888 scans with 1024 points in the 1H dimension and 100 points in 



















8.2 STD data of OPs binding to AChE-d S204A. 
 
Appendix 10.STD NMR experiment of azamethiphos in the presence and absence of AChE-d S204A. 
Azamethiphos concentrations were 0.5 mM and AChE-d S204A was 5.5 µM. The spectra were 






Appendix 11. STD NMR experiment of fenamiphos in the presence and absence of AChE-d S204A. 
Fenamiphos concentrations were 0.5 mM and AChE-d S204A was 5.5 µM. The spectra were 







Appendix 12. STD NMR experiment of methamidophos in the presence and absence of AChE-d 
S204A. Methamidophos concentrations were 0.5 mM and AChE-d S204A was 5.5 µM. The spectra 






Appendix 13. STD NMR experiment of soman in the presence and absence of AChE-d S204A. Soman 







Appendix 14. STD NMR experiment of tabun in the presence and absence of AChE-d S204A. Tabun 







Appendix 15. STD NMR experiment of VM in the presence and absence of AChE-d S204A. VM 







Appendix 16. STD NMR experiment of VX in the presence and absence of AChE-d S204A. VX 







Appendix 17. STD NMR experiment of cyclosarin in the presence and absence of AChE-d S204A. 
Cyclosarin concentrations were 0.5 mM and AChE-d S204A was 5.5 µM. The spectra were collected 
over 256 scans. 
 
